1dlh Citations

Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide.

Nature 368 215-21 (1994)
Cited: 788 times
EuropePMC logo PMID: 8145819


An influenza virus peptide binds to HLA-DR1 in an extended conformation with a pronounced twist. Thirty-five per cent of the peptide surface is accessible to solvent and potentially available for interaction with the antigen receptor on T cells. Pockets in the peptide-binding site accommodate five of the thirteen side chains of the bound peptide, and explain the peptide specificity of HLA-DR1. Twelve hydrogen bonds between conserved HLA-DR1 residues and the main chain of the peptide provide a universal mode of peptide binding, distinct from the strategy used by class I histocompatibility proteins.

Articles - 1dlh mentioned but not cited (1)

Reviews citing this publication (153)

  1. Major Histocompatibility Complex (MHC) Class I and MHC Class II Proteins: Conformational Plasticity in Antigen Presentation. Wieczorek M, Abualrous ET, Sticht J, Álvaro-Benito M, Stolzenberg S, Noé F, Freund C. Front Immunol 8 292 (2017)
  2. Major histocompatibility complex variation and the evolution of resistance to amphibian chytridiomycosis. Fu M, Waldman B. Immunogenetics 69 529-536 (2017)
  3. Variations in MHC Class II Antigen Processing and Presentation in Health and Disease. Unanue ER, Turk V, Neefjes J. Annu. Rev. Immunol. 34 265-297 (2016)
  4. The immunopathogenesis of staphylococcal skin infections - A review. Hill PB, Imai A. Comp. Immunol. Microbiol. Infect. Dis. 49 8-28 (2016)
  5. Present Yourself! By MHC Class I and MHC Class II Molecules. Rock KL, Reits E, Neefjes J. Trends Immunol. 37 724-737 (2016)
  6. A step-by-step overview of the dynamic process of epitope selection by major histocompatibility complex class II for presentation to helper T cells. Sadegh-Nasseri S. F1000Res 5 (2016)
  7. Fine-mapping the human leukocyte antigen locus in rheumatoid arthritis and other rheumatic diseases: identifying causal amino acid variants? van Heemst J, Huizinga TJ, van der Woude D, Toes RE. Curr Opin Rheumatol 27 256-261 (2015)
  8. Recent advances in the development of a chemically synthesised anti-malarial vaccine. Curtidor H, Patarroyo ME, Patarroyo MA. Expert Opin Biol Ther 15 1567-1581 (2015)
  9. Granuloma genes in sarcoidosis: what is new? Fischer A, Rybicki BA. Curr Opin Pulm Med 21 510-516 (2015)
  10. MHC structure and function – antigen presentation. Part 1. Goldberg AC, Rizzo LV. Einstein (Sao Paulo) 13 153-156 (2015)
  11. The versatility of the αβ T-cell antigen receptor. Bhati M, Cole DK, McCluskey J, Sewell AK, Rossjohn J. Protein Sci. 23 260-272 (2014)
  12. [A new mechanism of autoantibody production: antigen presentation of misfolded protein by MHC class II]. Ohmura K, Hiwa R, Arase H. Nihon Rinsho Meneki Gakkai Kaishi 37 462-467 (2014)
  13. The making of a sweet modification: structure and function of O-GlcNAc transferase. Janetzko J, Walker S. J. Biol. Chem. 289 34424-34432 (2014)
  14. Anti-citrullinated peptides as autoantigens in rheumatoid arthritis-relevance to treatment. Sakkas LI, Bogdanos DP, Katsiari C, Platsoucas CD. Autoimmun Rev 13 1114-1120 (2014)
  15. Immunological barriers to stem cell therapy in the central nervous system. Tullis GE, Spears K, Kirk MD. Stem Cells Int 2014 507905 (2014)
  16. Measurement of Peptide Binding to MHC Class II Molecules by Fluorescence Polarization. Yin L, Stern LJ. Curr Protoc Immunol 106 5.10.1-12 (2014)
  17. For many but not for all: how the conformational flexibility of the peptide/MHCII complex shapes epitope selection. Ferrante A. Immunol. Res. 56 85-95 (2013)
  18. Design of peptide immunotherapies for MHC Class-II-associated autoimmune disorders. Fridkis-Hareli M. Clin. Dev. Immunol. 2013 826191 (2013)
  19. A peptide's perspective on antigen presentation to the immune system. Neefjes J, Ovaa H. Nat. Chem. Biol. 9 769-775 (2013)
  20. Evaluating the immunogenicity of protein drugs by applying in vitro MHC binding data and the immune epitope database and analysis resource. Paul S, Kolla RV, Sidney J, Weiskopf D, Fleri W, Kim Y, Peters B, Sette A. Clin. Dev. Immunol. 2013 467852 (2013)
  21. HLA-DO and Its Role in MHC Class II Antigen Presentation. Poluektov YO, Kim A, Sadegh-Nasseri S. Front Immunol 4 260 (2013)
  22. Review of phosphocholine substituents on bacterial pathogen glycans: synthesis, structures and interactions with host proteins. Young NM, Foote SJ, Wakarchuk WW. Mol. Immunol. 56 563-573 (2013)
  23. Mechanisms of peptide repertoire selection by HLA-DM. Pos W, Sethi DK, Wucherpfennig KW. Trends Immunol. 34 495-501 (2013)
  24. Endoplasmic reticulum stress sensing in the unfolded protein response. Gardner BM, Pincus D, Gotthardt K, Gallagher CM, Walter P. Cold Spring Harb Perspect Biol 5 a013169 (2013)
  25. Pathways of antigen processing. Blum JS, Wearsch PA, Cresswell P. Annu. Rev. Immunol. 31 443-473 (2013)
  26. HLA class II molecules influence susceptibility versus protection in inflammatory diseases by determining the cytokine profile. Mangalam AK, Taneja V, David CS. J. Immunol. 190 513-518 (2013)
  27. Linkers in the structural biology of protein-protein interactions. Reddy Chichili VP, Kumar V, Sivaraman J. Protein Sci. 22 153-167 (2013)
  28. Structural basis of metal hypersensitivity. Wang Y, Dai S. Immunol. Res. 55 83-90 (2013)
  29. Antigen-specific blocking of CD4-specific immunological synapse formation using BPI and current therapies for autoimmune diseases. Manikwar P, Kiptoo P, Badawi AH, Büyüktimkin B, Siahaan TJ. Med Res Rev 32 727-764 (2012)
  30. Towards the development of a fully protective Plasmodium falciparum antimalarial vaccine. Patarroyo ME, Bermúdez A, Moreno-Vranich A. Expert Rev Vaccines 11 1057-1070 (2012)
  31. Conformational variation in structures of classical and non-classical MHCII proteins and functional implications. Painter CA, Stern LJ. Immunol. Rev. 250 144-157 (2012)
  32. Structural and dynamic control of T-cell receptor specificity, cross-reactivity, and binding mechanism. Baker BM, Scott DR, Blevins SJ, Hawse WF. Immunol. Rev. 250 10-31 (2012)
  33. The mechanism of HLA-DM induced peptide exchange in the MHC class II antigen presentation pathway. Schulze MS, Wucherpfennig KW. Curr. Opin. Immunol. 24 105-111 (2012)
  34. Small molecule modulators of MHC class II antigen presentation: mechanistic insights and implications for therapeutic application. Call MJ. Mol. Immunol. 48 1735-1743 (2011)
  35. Conformational heterogeneity of MHC class II induced upon binding to different peptides is a key regulator in antigen presentation and epitope selection. Sadegh-Nasseri S, Natarajan S, Chou CL, Hartman IZ, Narayan K, Kim A. Immunol. Res. 47 56-64 (2010)
  36. Quantum chemical analysis of MHC-peptide interactions for vaccine design. Agudelo WA, Patarroyo ME. Mini Rev Med Chem 10 746-758 (2010)
  37. CD4+ T cell epitope discovery and rational vaccine design. Rosa DS, Ribeiro SP, Cunha-Neto E. Arch. Immunol. Ther. Exp. (Warsz.) 58 121-130 (2010)
  38. Immunogenetics of drug-induced skin blistering disorders. Part II: synthesis. Bowman C, Delrieu O. Pharmacogenomics 10 779-816 (2009)
  39. In silico methods for predicting T-cell epitopes: Dr Jekyll or Mr Hyde? Gowthaman U, Agrewala JN. Expert Rev Proteomics 6 527-537 (2009)
  40. The molecular mechanisms of immunomodulation and tolerance induction to factor VIII. Waters B, Lillicrap D. J. Thromb. Haemost. 7 1446-1456 (2009)
  41. T cell allorecognition and MHC restriction--A case of Jekyll and Hyde? Archbold JK, Ely LK, Kjer-Nielsen L, Burrows SR, Rossjohn J, McCluskey J, Macdonald WA. Mol. Immunol. 45 583-598 (2008)
  42. Dissection of the multiple sclerosis associated DR2 haplotype. Etzensperger R, McMahon RM, Jones EY, Fugger L. J. Autoimmun. 31 201-207 (2008)
  43. Membrane-tethered proteins for basic research, imaging, and therapy. Cheng TL, Roffler S. Med Res Rev 28 885-928 (2008)
  44. Genetic factors affecting the occurrence, clinical phenotype, and outcome of autoimmune hepatitis. Czaja AJ. Clin. Gastroenterol. Hepatol. 6 379-388 (2008)
  45. Evolutionarily conserved amino acids that control TCR-MHC interaction. Marrack P, Scott-Browne JP, Dai S, Gapin L, Kappler JW. Annu. Rev. Immunol. 26 171-203 (2008)
  46. The convergent roles of tapasin and HLA-DM in antigen presentation. Sadegh-Nasseri S, Chen M, Narayan K, Bouvier M. Trends Immunol. 29 141-147 (2008)
  47. Influenza seasonality: underlying causes and modeling theories. Lofgren E, Fefferman NH, Naumov YN, Gorski J, Naumova EN. J. Virol. 81 5429-5436 (2007)
  48. The T cell antigen receptor: "The Hunting of the Snark". Mak TW. Eur. J. Immunol. 37 Suppl 1 S83-93 (2007)
  49. Polyspecificity of T cell and B cell receptor recognition. Wucherpfennig KW, Allen PM, Celada F, Cohen IR, De Boer R, Garcia KC, Goldstein B, Greenspan R, Hafler D, Hodgkin P, Huseby ES, Krakauer DC, Nemazee D, Perelson AS, Pinilla C, Strong RK, Sercarz EE. Semin. Immunol. 19 216-224 (2007)
  50. Mouse models of efficient and inefficient anti-tumor immunity, with emphasis on minimal residual disease and tumor escape. Egorov IK. Cancer Immunol. Immunother. 55 1-22 (2006)
  51. When T cells recognize a pattern, they might cause trouble. Sospedra M, Martin R. Curr. Opin. Immunol. 18 697-703 (2006)
  52. HLA and leprosy in the pre and postgenomic eras. Geluk A, Ottenhoff TH. Hum. Immunol. 67 439-445 (2006)
  53. MHC class II proteins and disease: a structural perspective. Jones EY, Fugger L, Strominger JL, Siebold C. Nat. Rev. Immunol. 6 271-282 (2006)
  54. A gut feeling for joint inflammation - using coeliac disease to understand rheumatoid arthritis. Molberg Ø, Sollid LM. Trends Immunol. 27 188-194 (2006)
  55. Genetic susceptibility to mycobacterial disease in humans. Fernando SL, Britton WJ. Immunol. Cell Biol. 84 125-137 (2006)
  56. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Knutson KL, Disis ML. Cancer Immunol. Immunother. 54 721-728 (2005)
  57. Gastrointestinal nematode infection in sheep--a review of the alternatives to anthelmintics in parasite control. Sayers G, Sweeney T. Anim Health Res Rev 6 159-171 (2005)
  58. Presentation of a self-peptide in two distinct conformations by a disease-associated HLA-B27 subtype. Wucherpfennig KW. J. Exp. Med. 199 151-154 (2004)
  59. Computational methods for prediction of T-cell epitopes--a framework for modelling, testing, and applications. Brusic V, Bajic VB, Petrovsky N. Methods 34 436-443 (2004)
  60. Molecular aspects of type 1 diabetes. Kelly MA, Rayner ML, Mijovic CH, Barnett AH. MP, Mol. Pathol. 56 1-10 (2003)
  61. Chronic beryllium disease: immune-mediated destruction with implications for organ-specific autoimmunity. Fontenot AP, Kotzin BL. Tissue Antigens 62 449-458 (2003)
  62. Evolving concepts of rheumatoid arthritis. Firestein GS. Nature 423 356-361 (2003)
  63. Molecular properties of HLA-DQ alleles conferring susceptibility to or protection from insulin-dependent diabetes mellitus: keys to the fate of islet beta-cells. Moustakas AK, Papadopoulos GK. Am. J. Med. Genet. 115 37-47 (2002)
  64. Polyproline II structure in proteins: identification by chiroptical spectroscopies, stability, and functions. Bochicchio B, Tamburro AM. Chirality 14 782-792 (2002)
  65. Perspective on antigen processing and presentation. Unanue ER. Immunol. Rev. 185 86-102 (2002)
  66. Beryllium disease. Saltini C, Amicosante M. Am. J. Med. Sci. 321 89-98 (2001)
  67. Immunogenetics in PSC. Donaldson PT, Norris S. Best Pract Res Clin Gastroenterol 15 611-627 (2001)
  68. Chronic beryllium disease: T cell recognition of a metal presented by HLA-DP. Fontenot AP, Newman LS, Kotzin BL. Clin. Immunol. 100 4-14 (2001)
  69. Peptide vaccines and peptide libraries. Wiesmüller KH, Fleckenstein B, Jung G. Biol. Chem. 382 571-579 (2001)
  70. Structural basis of molecular mimicry. Wucherpfennig KW. J. Autoimmun. 16 293-302 (2001)
  71. Self-reactive T cells and degeneracy of T cell recognition: evolving concepts-from sequence homology to shape mimicry and TCR flexibility. Maverakis E, van den Elzen P, Sercarz EE. J. Autoimmun. 16 201-209 (2001)
  72. HLA-DQ6-mediated protection in IDDM. Sanjeevi CB. Hum. Immunol. 61 148-153 (2000)
  73. The new architectonics: an invitation to structural biology. Schutt CE, Lindberg U. Anat. Rec. 261 198-215 (2000)
  74. Nonclassical MHC class II molecules. Alfonso C, Karlsson L. Annu. Rev. Immunol. 18 113-142 (2000)
  75. Rous-Whipple Award Lecture. Chemical features of peptide selection by the class II histocompatibility molecules. Unanue ER. Am. J. Pathol. 154 651-664 (1999)
  76. HLA-DM and the MHC class II antigen presentation pathway. Jensen PE, Weber DA, Thayer WP, Chen X, Dao CT. Immunol. Res. 20 195-205 (1999)
  77. The impact of the non-classical MHC proteins HLA-DM and HLA-DO on loading of MHC class II molecules. Kropshofer H, Hämmerling GJ, Vogt AB. Immunol. Rev. 172 267-278 (1999)
  78. Peptide exchange in MHC molecules. Jensen PE, Weber DA, Thayer WP, Westerman LE, Dao CT. Immunol. Rev. 172 229-238 (1999)
  79. Mechanisms and consequences of peptide selection by the I-Ak class II molecule. Latek RR, Unanue ER. Immunol. Rev. 172 209-228 (1999)
  80. Intracellular transport and peptide loading of MHC class II molecules: regulation by chaperones and motors. Wubbolts R, Neefjes J. Immunol. Rev. 172 189-208 (1999)
  81. Quantitative analysis of peptide-MHC class II interaction. Fleckenstein B, Jung G, Wiesmüller KH. Semin. Immunol. 11 405-416 (1999)
  82. Quality control of MHC class II associated peptides by HLA-DM/H2-M. Vogt AB, Arndt SO, Hämmerling GJ, Kropshofer H. Semin. Immunol. 11 391-403 (1999)
  83. Superantigens: mechanisms by which they may induce, exacerbate and control autoimmune diseases. Macphail S. Int. Rev. Immunol. 18 141-180 (1999)
  84. HLA polymorphisms and T cells in rheumatoid arthritis. Weyand CM, Goronzy JJ. Int. Rev. Immunol. 18 37-59 (1999)
  85. MHC superfamily structure and the immune system. Maenaka K, Jones EY. Curr. Opin. Struct. Biol. 9 745-753 (1999)
  86. Synthetic peptide vaccines effective in preventing virus infection. Ogasawara K. Microbiol. Immunol. 43 915-923 (1999)
  87. The HLA complex in Goodpasture's disease: a model for analyzing susceptibility to autoimmunity. Phelps RG, Rees AJ. Kidney Int. 56 1638-1653 (1999)
  88. HLA class II restriction of autoreactive T cell responses in pemphigus vulgaris: review of the literature and potential applications for the development of a specific immunotherapy. Riechers R, Grötzinger J, Hertl M. Autoimmunity 30 183-196 (1999)
  89. Structural basis of T cell recognition. Garcia KC, Teyton L, Wilson IA. Annu. Rev. Immunol. 17 369-397 (1999)
  90. Mechanisms of antigen presentation. Jensen PE. Clin. Chem. Lab. Med. 37 179-186 (1999)
  91. MHC-restricted antigen presentation and recognition: constraints on gene, recombinant and peptide vaccines in humans. Cunha-Neto E. Braz. J. Med. Biol. Res. 32 199-205 (1999)
  92. Exploring immunological specificity using synthetic peptide combinatorial libraries. Pinilla C, Martin R, Gran B, Appel JR, Boggiano C, Wilson DB, Houghten RA. Curr. Opin. Immunol. 11 193-202 (1999)
  93. Comparative organization and function of the major histocompatibility complex of domesticated cattle. Lewin HA, Russell GC, Glass EJ. Immunol. Rev. 167 145-158 (1999)
  94. Evolution of the mammalian MHC: natural selection, recombination, and convergent evolution. Yeager M, Hughes AL. Immunol. Rev. 167 45-58 (1999)
  95. MHC structure and function. Thorsby E. Transplant. Proc. 31 713-716 (1999)
  96. Peptide-based molecular analyses of HLA class II-associated susceptibility to autoimmune diseases. Nishimura Y, Oiso M, Fujisao S, Kanai T, Kira J, Chen YZ, Matsushita S. Int. Rev. Immunol. 17 229-262 (1998)
  97. Molecular analyses of HLA class II-associated susceptibility to subtypes of autoimmune diseases unique to Asians. Nishimura Y, Kanai T, Oiso M, Tabata H, Ito H, Kira J, Chen YZ, Matsushita S. Int. J. Cardiol. 66 Suppl 1 S93-104 (1998)
  98. From peptides to peptidomimetics: design of nonpeptide ligands for major histocompatibility proteins. Krebs S, Rognan D. Pharm Acta Helv 73 173-181 (1998)
  99. The optimization of helper T lymphocyte (HTL) function in vaccine development. Alexander J, Fikes J, Hoffman S, Franke E, Sacci J, Appella E, Chisari FV, Guidotti LG, Chesnut RW, Livingston B, Sette A. Immunol. Res. 18 79-92 (1998)
  100. An accessory peptide binding site with allosteric effect on the formation of peptide-MHC-II complexes? Gerlier D, Trescol-Biémont MC, Ettouati L, Paris J, Rabourdin-Combe C. C. R. Acad. Sci. III, Sci. Vie 321 19-24 (1998)
  101. The CD1 family of lipid antigen-presenting molecules. Porcelli SA, Segelke BW, Sugita M, Wilson IA, Brenner MB. Immunol. Today 19 362-368 (1998)
  102. The modular architecture of leukocyte cell-surface receptors. Campbell ID. Immunol. Rev. 163 11-18 (1998)
  103. Thymus, thymoma, and specific T cells in myasthenia gravis. Beeson D, Bond AP, Corlett L, Curnow SJ, Hill ME, Jacobson LW, MacLennan C, Meager A, Moody AM, Moss P, Nagvekar N, Newsom-Davis J, Pantic N, Roxanis I, Spack EG, Vincent A, Willcox N. Ann. N. Y. Acad. Sci. 841 371-387 (1998)
  104. T cell recognition of the acetylcholine receptor in myasthenia gravis. Conti-Fine BM, Navaneetham D, Karachunski PI, Raju R, Diethelm-Okita B, Okita D, Howard J, Wang ZY. Ann. N. Y. Acad. Sci. 841 283-308 (1998)
  105. Presentation of antigenic peptides by products of the major histocompatibility complex. Fairchild PJ. J. Pept. Sci. 4 182-194 (1998)
  106. The peptide-binding strategy of the MHC class II I-A molecules. Reizis B, Eisenstein M, Mor F, Cohen IR. Immunol. Today 19 212-216 (1998)
  107. Autoimmune diabetes: the role of T cells, MHC molecules and autoantigens. Durinovic-Belló I. Autoimmunity 27 159-177 (1998)
  108. Unusual MHC-like molecules: CD1, Fc receptor, the hemochromatosis gene product, and viral homologs. Wilson IA, Bjorkman PJ. Curr. Opin. Immunol. 10 67-73 (1998)
  109. Reevaluation of the importance of polymorphic HLA class II alleles and amino acids in the susceptibility of individuals of different populations to type I diabetes. Zamani M, Cassiman JJ. Am. J. Med. Genet. 76 183-194 (1998)
  110. Molecular features of penicillin allergy. Weltzien HU, Padovan E. J. Invest. Dermatol. 110 203-206 (1998)
  111. MHC class II restricted antigen presentation. Pieters J. Curr. Opin. Immunol. 9 89-96 (1997)
  112. Implications of atomic-resolution structures for cell adhesion. Leahy DJ. Annu. Rev. Cell Dev. Biol. 13 363-393 (1997)
  113. Structural and mechanistic consequences of polypeptide binding by GroEL. Coyle JE, Jaeger J, Gross M, Robinson CV, Radford SE. Fold Des 2 R93-104 (1997)
  114. The tetramer model: a new view of class II MHC molecules in antigenic presentation to T cells. Pareja E, Tobes R, Martín J, Nieto A. Tissue Antigens 50 421-428 (1997)
  115. Selection of the MHC class II-associated peptide repertoire by HLA-DM. Arndt SO, Vogt AB, Hämmerling GJ, Kropshofer H. Immunol. Res. 16 261-272 (1997)
  116. Conformational changes in MHC class I molecules. Antibody, T-cell receptor, and NK cell recognition in an HLA-B7 model system. Smith KD, Kurago ZB, Lutz CT. Immunol. Res. 16 243-259 (1997)
  117. Endosomal proteases and antigen processing. Fineschi B, Miller J. Trends Biochem. Sci. 22 377-382 (1997)
  118. Genetic influences on sarcoidosis. Ishihara M, Ohno S. Eye (Lond) 11 ( Pt 2) 155-161 (1997)
  119. Peptide binding and antigen presentation by class II histocompatibility glycoproteins. Jensen PE. Biopolymers 43 303-322 (1997)
  120. Peptide binding by class I and class II MHC molecules. Batalia MA, Collins EJ. Biopolymers 43 281-302 (1997)
  121. MHC class II-dependent peptide antigen versus superantigen presentation to T cells. Shoukry NH, Lavoie PM, Thibodeau J, D'Souza S, Sekaly RP. Hum. Immunol. 54 194-201 (1997)
  122. Parameters affecting the immunogenicity of recombinant T cell epitopes inserted into hybrid proteins. Lo-Man R, Leclerc C. Hum. Immunol. 54 180-188 (1997)
  123. How HLA-DM affects the peptide repertoire bound to HLA-DR molecules. Vogt AB, Kropshofer H, Hämmerling GJ. Hum. Immunol. 54 170-179 (1997)
  124. Antigen presentation by MHC class II molecules: invariant chain function, protein trafficking, and the molecular basis of diverse determinant capture. Castellino F, Zhong G, Germain RN. Hum. Immunol. 54 159-169 (1997)
  125. Antigen presentation by MHC class II molecules. Weenink SM, Gautam AM. Immunol. Cell Biol. 75 69-81 (1997)
  126. The roles of the human major histocompatibility complex and human papillomavirus infection in cervical intraepithelial neoplasia and cervical cancer. Odunsi KO, Ganesan TS. Clin Oncol (R Coll Radiol) 9 4-13 (1997)
  127. Biophysical and structural studies of TCRs and ligands: implications for T cell signaling. Ward ES, Qadri A. Curr. Opin. Immunol. 9 97-106 (1997)
  128. MHC class I and class II structures. Jones EY. Curr. Opin. Immunol. 9 75-79 (1997)
  129. Invariant chain structure and MHC class II function. Cresswell P. Cell 84 505-507 (1996)
  130. Heritable factors distinguish two types of alopecia areata. Price VH, Colombe BW. Dermatol Clin 14 679-689 (1996)
  131. Appreciating the complexity of MHC class II peptide binding: lysozyme peptide and I-Ak. Nelson CA, Viner NJ, Unanue ER. Immunol. Rev. 151 81-105 (1996)
  132. Processing and presentation of endocytically acquired protein antigens by MHC class II and class I molecules. German RN, Castellino F, Han R, Reis e Sousa C, Romagnoli P, Sadegh-Nasseri S, Zhong GM. Immunol. Rev. 151 5-30 (1996)
  133. A high affinity T cell receptor? Alberti S. Immunol. Cell Biol. 74 292-297 (1996)
  134. Reverse immunogenetics: from HLA-disease associations to vaccine candidates. Davenport MP, Hill AV. Mol Med Today 2 38-45 (1996)
  135. Structure of HLA molecules and immunosuppressive effects of HLA derived peptides. Krensky AM, Clayberger C. Int. Rev. Immunol. 13 173-185 (1996)
  136. Biophysical studies of T-cell receptors and their ligands. Fremont DH, Rees WA, Kozono H. Curr. Opin. Immunol. 8 93-100 (1996)
  137. Developing and shedding inhibitions: how MHC class II molecules reach maturity. Busch R, Mellins ED. Curr. Opin. Immunol. 8 51-58 (1996)
  138. The chemistry of signal transduction. Clardy J. Proc. Natl. Acad. Sci. U.S.A. 92 56-61 (1995)
  139. Molecular recognition of antigen involves lattice formation between CD4, MHC class II and TCR molecules. Sakihama T, Smolyar A, Reinherz EL. Immunol. Today 16 581-587 (1995)
  140. Protein-peptide interactions. Stanfield RL, Wilson IA. Curr. Opin. Struct. Biol. 5 103-113 (1995)
  141. Chemistry of peptides associated with MHC class I and class II molecules. Rammensee HG. Curr. Opin. Immunol. 7 85-96 (1995)
  142. The role of the trimolecular complex (alpha beta TCR-MHC+peptide) in the pathogenesis of systemic sclerosis. Dwyer E, Winchester R. Int. Rev. Immunol. 12 85-96 (1995)
  143. Oligoclonality in the CD8+ T-cell population. Analysis using a multiplex PCR assay for CDR3 length. Gregersen PK, Hingorani R, Monteiro J. Ann. N. Y. Acad. Sci. 756 19-27 (1995)
  144. Genetic contributions to lupus-like disease in (NZB x NZW)F1 mice. Drake CG, Rozzo SJ, Vyse TJ, Palmer E, Kotzin BL. Immunol. Rev. 144 51-74 (1995)
  145. The gluten-host interaction. Tighe MR, Ciclitira PJ. Baillieres Clin. Gastroenterol. 9 211-230 (1995)
  146. New methods to predict MHC-binding sequences within protein antigens. Hammer J. Curr. Opin. Immunol. 7 263-269 (1995)
  147. The importance of extended conformations and, in particular, the PII conformation for the molecular recognition of peptides. Siligardi G, Drake AF. Biopolymers 37 281-292 (1995)
  148. Antibody-antigen interactions: new structures and new conformational changes. Wilson IA, Stanfield RL. Curr. Opin. Struct. Biol. 4 857-867 (1994)
  149. Structures of two classes of MHC molecules elucidated: crucial differences and similarities. Bjorkman PJ, Burmeister WP. Curr. Opin. Struct. Biol. 4 852-856 (1994)
  150. The genes influencing the susceptibility to IDDM in humans. Faas S, Trucco M. J. Endocrinol. Invest. 17 477-495 (1994)
  151. Substrate and pseudosubstrate interactions with protein kinases: determinants of specificity. Kemp BE, Parker MW, Hu S, Tiganis T, House C. Trends Biochem. Sci. 19 440-444 (1994)
  152. Antigen presentation. One size fits all. Rothbard JB. Curr. Biol. 4 653-655 (1994)
  153. Antigenic peptide binding by class I and class II histocompatibility proteins. Stern LJ, Wiley DC. Structure 2 245-251 (1994)

Articles citing this publication (634)

  1. Crystallographic analysis of the recognition of a nuclear localization signal by the nuclear import factor karyopherin alpha. Conti E, Uy M, Leighton L, Blobel G, Kuriyan J. Cell 94 193-204 (1998)
  2. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Ghosh P, Amaya M, Mellins E, Wiley DC. Nature 378 457-462 (1995)
  3. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Alexander J, Sidney J, Southwood S, Ruppert J, Oseroff C, Maewal A, Snoke K, Serra HM, Kubo RT, Sette A. Immunity 1 751-761 (1994)
  4. MR1 presents microbial vitamin B metabolites to MAIT cells. Kjer-Nielsen L, Patel O, Corbett AJ, Le Nours J, Meehan B, Liu L, Bhati M, Chen Z, Kostenko L, Reantragoon R, Williamson NA, Purcell AW, Dudek NL, McConville MJ, O'Hair RA, Khairallah GN, Godfrey DI, Fairlie DP, Rossjohn J, McCluskey J. Nature 491 717-723 (2012)
  5. A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. Wang P, Sidney J, Dow C, Mothé B, Sette A, Peters B. PLoS Comput. Biol. 4 e1000048 (2008)
  6. MHC class II tetramers identify peptide-specific human CD4(+) T cells proliferating in response to influenza A antigen. Novak EJ, Liu AW, Nepom GT, Kwok WW. J. Clin. Invest. 104 R63-7 (1999)
  7. Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. Maecker HT, Dunn HS, Suni MA, Khatamzas E, Pitcher CJ, Bunde T, Persaud N, Trigona W, Fu TM, Sinclair E, Bredt BM, McCune JM, Maino VC, Kern F, Picker LJ. J. Immunol. Methods 255 27-40 (2001)
  8. Propagating structure of Alzheimer's beta-amyloid(10-35) is parallel beta-sheet with residues in exact register. Benzinger TL, Gregory DM, Burkoth TS, Miller-Auer H, Lynn DG, Botto RE, Meredith SC. Proc. Natl. Acad. Sci. U.S.A. 95 13407-13412 (1998)
  9. X-ray crystal structure of HLA-DR4 (DRA*0101, DRB1*0401) complexed with a peptide from human collagen II. Dessen A, Lawrence CM, Cupo S, Zaller DM, Wiley DC. Immunity 7 473-481 (1997)
  10. Structural basis for HLA-DQ2-mediated presentation of gluten epitopes in celiac disease. Kim CY, Quarsten H, Bergseng E, Khosla C, Sollid LM. Proc. Natl. Acad. Sci. U.S.A. 101 4175-4179 (2004)
  11. HLA DRB4 0101-restricted immunodominant T cell autoepitope of pyruvate dehydrogenase complex in primary biliary cirrhosis: evidence of molecular mimicry in human autoimmune diseases. Shimoda S, Nakamura M, Ishibashi H, Hayashida K, Niho Y. J. Exp. Med. 181 1835-1845 (1995)
  12. Peptide binding specificity of HLA-DR4 molecules: correlation with rheumatoid arthritis association. Hammer J, Gallazzi F, Bono E, Karr RW, Guenot J, Valsasnini P, Nagy ZA, Sinigaglia F. J. Exp. Med. 181 1847-1855 (1995)
  13. Identification of high potency microbial and self ligands for a human autoreactive class II-restricted T cell clone. Hemmer B, Fleckenstein BT, Vergelli M, Jung G, McFarland H, Martin R, Wiesmüller KH. J. Exp. Med. 185 1651-1659 (1997)
  14. Structure of a covalently stabilized complex of a human alphabeta T-cell receptor, influenza HA peptide and MHC class II molecule, HLA-DR1. Hennecke J, Carfi A, Wiley DC. EMBO J. 19 5611-5624 (2000)
  15. Crystal structure of HLA-DR2 (DRA*0101, DRB1*1501) complexed with a peptide from human myelin basic protein. Smith KJ, Pyrdol J, Gauthier L, Wiley DC, Wucherpfennig KW. J. Exp. Med. 188 1511-1520 (1998)
  16. Precise prediction of major histocompatibility complex class II-peptide interaction based on peptide side chain scanning. Hammer J, Bono E, Gallazzi F, Belunis C, Nagy Z, Sinigaglia F. J. Exp. Med. 180 2353-2358 (1994)
  17. Editing of the HLA-DR-peptide repertoire by HLA-DM. Kropshofer H, Vogt AB, Moldenhauer G, Hammer J, Blum JS, Hämmerling GJ. EMBO J. 15 6144-6154 (1996)
  18. Crystal structures of two I-Ad-peptide complexes reveal that high affinity can be achieved without large anchor residues. Scott CA, Peterson PA, Teyton L, Wilson IA. Immunity 8 319-329 (1998)
  19. The structural basis for the recognition of diverse receptor sequences by TRAF2. Ye H, Park YC, Kreishman M, Kieff E, Wu H. Mol. Cell 4 321-330 (1999)
  20. The relationship of MHC-peptide binding and T cell activation probed using chemically defined MHC class II oligomers. Cochran JR, Cameron TO, Stern LJ. Immunity 12 241-250 (2000)
  21. High-resolution crystal structures of tyrosine kinase SH3 domains complexed with proline-rich peptides. Musacchio A, Saraste M, Wilmanns M. Nat. Struct. Biol. 1 546-551 (1994)
  22. Crystal structure of I-Ak in complex with a dominant epitope of lysozyme. Fremont DH, Monnaie D, Nelson CA, Hendrickson WA, Unanue ER. Immunity 8 305-317 (1998)
  23. The CLIP region of invariant chain plays a critical role in regulating major histocompatibility complex class II folding, transport, and peptide occupancy. Romagnoli P, Germain RN. J. Exp. Med. 180 1107-1113 (1994)
  24. Structural basis for major histocompatibility complex (MHC)-linked susceptibility to autoimmunity: charged residues of a single MHC binding pocket confer selective presentation of self-peptides in pemphigus vulgaris. Wucherpfennig KW, Yu B, Bhol K, Monos DS, Argyris E, Karr RW, Ahmed AR, Strominger JL. Proc. Natl. Acad. Sci. U.S.A. 92 11935-11939 (1995)
  25. Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression. Campbell JD, Buckland KF, McMillan SJ, Kearley J, Oldfield WL, Stern LJ, Grönlund H, van Hage M, Reynolds CJ, Boyton RJ, Cobbold SP, Kay AB, Altmann DM, Lloyd CM, Larché M. J. Exp. Med. 206 1535-1547 (2009)
  26. Crystallographic analysis of endogenous peptides associated with HLA-DR1 suggests a common, polyproline II-like conformation for bound peptides. Jardetzky TS, Brown JH, Gorga JC, Stern LJ, Urban RG, Strominger JL, Wiley DC. Proc. Natl. Acad. Sci. U.S.A. 93 734-738 (1996)
  27. Specific T cell recognition of minimally homologous peptides: evidence for multiple endogenous ligands. Evavold BD, Sloan-Lancaster J, Wilson KJ, Rothbard JB, Allen PM. Immunity 2 655-663 (1995)
  28. Selective binding of self peptides to disease-associated major histocompatibility complex (MHC) molecules: a mechanism for MHC-linked susceptibility to human autoimmune diseases. Wucherpfennig KW, Strominger JL. J. Exp. Med. 181 1597-1601 (1995)
  29. The specificity and orientation of a TCR to its peptide-MHC class II ligands. Sant'Angelo DB, Waterbury G, Preston-Hurlburt P, Yoon ST, Medzhitov R, Hong SC, Janeway CA. Immunity 4 367-376 (1996)
  30. Recognition of the immunodominant myelin basic protein peptide by autoantibodies and HLA-DR2-restricted T cell clones from multiple sclerosis patients. Identity of key contact residues in the B-cell and T-cell epitopes. Wucherpfennig KW, Catz I, Hausmann S, Strominger JL, Steinman L, Warren KG. J. Clin. Invest. 100 1114-1122 (1997)
  31. Structural basis of peptide binding and presentation by the type I diabetes-associated MHC class II molecule of NOD mice. Latek RR, Suri A, Petzold SJ, Nelson CA, Kanagawa O, Unanue ER, Fremont DH. Immunity 12 699-710 (2000)
  32. Human cartilage glycoprotein-39 as a candidate autoantigen in rheumatoid arthritis. Verheijden GF, Rijnders AW, Bos E, Coenen-de Roo CJ, van Staveren CJ, Miltenburg AM, Meijerink JH, Elewaut D, de Keyser F, Veys E, Boots AM. Arthritis Rheum. 40 1115-1125 (1997)
  33. Characterization of two distinct MHC class II binding sites in the superantigen staphylococcal enterotoxin A. Abrahmsén L, Dohlsten M, Segrén S, Björk P, Jonsson E, Kalland T. EMBO J. 14 2978-2986 (1995)
  34. Pediatric and adult forms of type I autoimmune hepatitis in Argentina: evidence for differential genetic predisposition. Pando M, Larriba J, Fernandez GC, Fainboim H, Ciocca M, Ramonet M, Badia I, Daruich J, Findor J, Tanno H, Cañero-Velasco C, Fainboim L. Hepatology 30 1374-1380 (1999)
  35. Development and characterization of desmoglein-3 specific T cells from patients with pemphigus vulgaris. Lin MS, Swartz SJ, Lopez A, Ding X, Fernandez-Vina MA, Stastny P, Fairley JA, Diaz LA. J. Clin. Invest. 99 31-40 (1997)
  36. Structure of a complex of the human alpha/beta T cell receptor (TCR) HA1.7, influenza hemagglutinin peptide, and major histocompatibility complex class II molecule, HLA-DR4 (DRA*0101 and DRB1*0401): insight into TCR cross-restriction and alloreactivity. Hennecke J, Wiley DC. J. Exp. Med. 195 571-581 (2002)
  37. Association between HLA-DM and HLA-DR in vivo. Sanderson F, Thomas C, Neefjes J, Trowsdale J. Immunity 4 87-96 (1996)
  38. Characterization and quantitation of peptide-MHC complexes produced from hen egg lysozyme using a monoclonal antibody. Dadaglio G, Nelson CA, Deck MB, Petzold SJ, Unanue ER. Immunity 6 727-738 (1997)
  39. The alphabeta T cell response to self-glycolipids shows a novel mechanism of CD1b loading and a requirement for complex oligosaccharides. Shamshiev A, Donda A, Prigozy TI, Mori L, Chigorno V, Benedict CA, Kappos L, Sonnino S, Kronenberg M, De Libero G. Immunity 13 255-264 (2000)
  40. T cell receptor recognition of MHC class II-bound peptide flanking residues enhances immunogenicity and results in altered TCR V region usage. Carson RT, Vignali KM, Woodland DL, Vignali DA. Immunity 7 387-399 (1997)
  41. The peptide binding motif of the disease associated HLA-DQ (alpha 1* 0501, beta 1* 0201) molecule. Vartdal F, Johansen BH, Friede T, Thorpe CJ, Stevanović S, Eriksen JE, Sletten K, Thorsby E, Rammensee HG, Sollid LM. Eur. J. Immunol. 26 2764-2772 (1996)
  42. Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1 and 2. Bittencourt PL, Goldberg AC, Cançado EL, Porta G, Carrilho FJ, Farias AQ, Palacios SA, Chiarella JM, Abrantes-Lemos CP, Baggio VL, Laudanna AA, Kalil J. Am. J. Gastroenterol. 94 1906-1913 (1999)
  43. Peptide binding characteristics of the coeliac disease-associated DQ(alpha1*0501, beta1*0201) molecule. van de Wal Y, Kooy YM, Drijfhout JW, Amons R, Koning F. Immunogenetics 44 246-253 (1996)
  44. Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35). Loftus DJ, Castelli C, Clay TM, Squarcina P, Marincola FM, Nishimura MI, Parmiani G, Appella E, Rivoltini L. J. Exp. Med. 184 647-657 (1996)
  45. Functional classification of class II human leukocyte antigen (HLA) molecules reveals seven different supertypes and a surprising degree of repertoire sharing across supertypes. Greenbaum J, Sidney J, Chung J, Brander C, Peters B, Sette A. Immunogenetics 63 325-335 (2011)
  46. The structure of HLA-DM, the peptide exchange catalyst that loads antigen onto class II MHC molecules during antigen presentation. Mosyak L, Zaller DM, Wiley DC. Immunity 9 377-383 (1998)
  47. Biochemical identification of a mutated human melanoma antigen recognized by CD4(+) T cells. Pieper R, Christian RE, Gonzales MI, Nishimura MI, Gupta G, Settlage RE, Shabanowitz J, Rosenberg SA, Hunt DF, Topalian SL. J. Exp. Med. 189 757-766 (1999)
  48. Supermotifs enable natural invariant chain-derived peptides to interact with many major histocompatibility complex-class II molecules. Malcherek G, Gnau V, Jung G, Rammensee HG, Melms A. J. Exp. Med. 181 527-536 (1995)
  49. Prediction of CTL epitopes using QM, SVM and ANN techniques. Bhasin M, Raghava GP. Vaccine 22 3195-3204 (2004)
  50. Abundant empty class II MHC molecules on the surface of immature dendritic cells. Santambrogio L, Sato AK, Fischer FR, Dorf ME, Stern LJ. Proc. Natl. Acad. Sci. U.S.A. 96 15050-15055 (1999)
  51. A structural and immunological basis for the role of human leukocyte antigen DQ8 in celiac disease. Henderson KN, Tye-Din JA, Reid HH, Chen Z, Borg NA, Beissbarth T, Tatham A, Mannering SI, Purcell AW, Dudek NL, van Heel DA, McCluskey J, Rossjohn J, Anderson RP. Immunity 27 23-34 (2007)
  52. Definition of MHC and T cell receptor contacts in the HLA-DR4restricted immunodominant epitope in type II collagen and characterization of collagen-induced arthritis in HLA-DR4 and human CD4 transgenic mice. Andersson EC, Hansen BE, Jacobsen H, Madsen LS, Andersen CB, Engberg J, Rothbard JB, McDevitt GS, Malmström V, Holmdahl R, Svejgaard A, Fugger L. Proc. Natl. Acad. Sci. U.S.A. 95 7574-7579 (1998)
  53. The class II MHC protein HLA-DR1 in complex with an endogenous peptide: implications for the structural basis of the specificity of peptide binding. Murthy VL, Stern LJ. Structure 5 1385-1396 (1997)
  54. Formation of a highly peptide-receptive state of class II MHC. Rabinowitz JD, Vrljic M, Kasson PM, Liang MN, Busch R, Boniface JJ, Davis MM, McConnell HM. Immunity 9 699-709 (1998)
  55. HLA class II alleles, genotypes, haplotypes, and amino acids in primary biliary cirrhosis: a large-scale study. Donaldson PT, Baragiotta A, Heneghan MA, Floreani A, Venturi C, Underhill JA, Jones DE, James OF, Bassendine MF. Hepatology 44 667-674 (2006)
  56. Multiple binding sites for bacterial superantigens on soluble class II MHC molecules. Kozono H, Parker D, White J, Marrack P, Kappler J. Immunity 3 187-196 (1995)
  57. HLA-DM recognizes the flexible conformation of major histocompatibility complex class II. Chou CL, Sadegh-Nasseri S. J. Exp. Med. 192 1697-1706 (2000)
  58. Beryllium presentation to CD4+ T cells underlies disease-susceptibility HLA-DP alleles in chronic beryllium disease. Fontenot AP, Torres M, Marshall WH, Newman LS, Kotzin BL. Proc. Natl. Acad. Sci. U.S.A. 97 12717-12722 (2000)
  59. Pocket 4 of the HLA-DR(alpha,beta 1*0401) molecule is a major determinant of T cells recognition of peptide. Fu XT, Bono CP, Woulfe SL, Swearingen C, Summers NL, Sinigaglia F, Sette A, Schwartz BD, Karr RW. J. Exp. Med. 181 915-926 (1995)
  60. Topology of the CD2-CD48 cell-adhesion molecule complex: implications for antigen recognition by T cells. van der Merwe PA, McNamee PN, Davies EA, Barclay AN, Davis SJ. Curr. Biol. 5 74-84 (1995)
  61. The spectrum of HLA-DQ and HLA-DR alleles, 2006: a listing correlating sequence and structure with function. Bondinas GP, Moustakas AK, Papadopoulos GK. Immunogenetics 59 539-553 (2007)
  62. Structure of the Epstein-Barr virus gp42 protein bound to the MHC class II receptor HLA-DR1. Mullen MM, Haan KM, Longnecker R, Jardetzky TS. Mol. Cell 9 375-385 (2002)
  63. MULTIPRED: a computational system for prediction of promiscuous HLA binding peptides. Zhang GL, Khan AM, Srinivasan KN, August JT, Brusic V. Nucleic Acids Res. 33 W172-9 (2005)
  64. T cell subsets, epitope mapping, and HLA-restriction in patients with allergic bronchopulmonary aspergillosis. Chauhan B, Knutsen Ap, Hutcheson PS, Slavin RG, Bellone CJ. J. Clin. Invest. 97 2324-2331 (1996)
  65. Specificity of an HLA-DRB1*0401-restricted T cell response to type II collagen. Fugger L, Rothbard JB, Sonderstrup-McDevitt G. Eur. J. Immunol. 26 928-933 (1996)
  66. Crystal structure of the HLA-Cw3 allotype-specific killer cell inhibitory receptor KIR2DL2. Snyder GA, Brooks AG, Sun PD. Proc. Natl. Acad. Sci. U.S.A. 96 3864-3869 (1999)
  67. Pathogenesis of rheumatoid arthritis. Weyand CM, Goronzy JJ. Med. Clin. North Am. 81 29-55 (1997)
  68. Binding interactions between peptides and proteins of the class II major histocompatibility complex. McFarland BJ, Beeson C. Med Res Rev 22 168-203 (2002)
  69. Empty and peptide-loaded class II major histocompatibility complex proteins produced by expression in Escherichia coli and folding in vitro. Frayser M, Sato AK, Xu L, Stern LJ. Protein Expr. Purif. 15 105-114 (1999)
  70. The distribution of DR4 haplotypes in Sardinia suggests a primary association of type I diabetes with DRB1 and DQB1 loci. Cucca F, Lampis R, Frau F, Macis D, Angius E, Masile P, Chessa M, Frongia P, Silvetti M, Cao A, De Virgiliis S, Congia M. Hum. Immunol. 43 301-308 (1995)
  71. Dendritic cells permit identification of genes encoding MHC class II-restricted epitopes of transplantation antigens. Scott D, Addey C, Ellis P, James E, Mitchell MJ, Saut N, Jurcevic S, Simpson E. Immunity 12 711-720 (2000)
  72. Crystal structure of a superantigen bound to the high-affinity, zinc-dependent site on MHC class II. Li Y, Li H, Dimasi N, McCormick JK, Martin R, Schuck P, Schlievert PM, Mariuzza RA. Immunity 14 93-104 (2001)
  73. Methods for MHC genotyping in non-model vertebrates. Babik W. Mol Ecol Resour 10 237-251 (2010)
  74. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis. Czaja AJ, Donaldson PT, Lohse AW. Am. J. Gastroenterol. 97 413-419 (2002)
  75. Allele specificity of structural requirement for peptides bound to HLA-DRB1*0405 and -DRB1*0406 complexes: implication for the HLA-associated susceptibility to methimazole-induced insulin autoimmune syndrome. Matsushita S, Takahashi K, Motoki M, Komoriya K, Ikagawa S, Nishimura Y. J. Exp. Med. 180 873-883 (1994)
  76. Penicilloyl peptides are recognized as T cell antigenic determinants in penicillin allergy. Padovan E, Bauer T, Tongio MM, Kalbacher H, Weltzien HU. Eur. J. Immunol. 27 1303-1307 (1997)
  77. Distinct antigen MHC class II complexes generated by separate processing pathways. Lindner R, Unanue ER. EMBO J. 15 6910-6920 (1996)
  78. T cell epitopes of insulin defined in HLA-DR4 transgenic mice are derived from preproinsulin and proinsulin. Congia M, Patel S, Cope AP, De Virgiliis S, Sønderstrup G. Proc. Natl. Acad. Sci. U.S.A. 95 3833-3838 (1998)
  79. Molecular analysis of HLA class II associations with hepatitis B virus clearance and vaccine nonresponsiveness. Godkin A, Davenport M, Hill AV. Hepatology 41 1383-1390 (2005)
  80. HLA-DQB1 codon 57 is critical for peptide binding and recognition. Kwok WW, Domeier ME, Johnson ML, Nepom GT, Koelle DM. J. Exp. Med. 183 1253-1258 (1996)
  81. Arginine at positions 13 or 70-71 in pocket 4 of HLA-DRB1 alleles is associated with susceptibility to tuberculoid leprosy. Zerva L, Cizman B, Mehra NK, Alahari SK, Murali R, Zmijewski CM, Kamoun M, Monos DS. J. Exp. Med. 183 829-836 (1996)
  82. Structural basis for the binding of an immunodominant peptide from myelin basic protein in different registers by two HLA-DR2 proteins. Li Y, Li H, Martin R, Mariuzza RA. J. Mol. Biol. 304 177-188 (2000)
  83. T cells distinguish MHC-peptide complexes formed in separate vesicles and edited by H2-DM. Pu Z, Lovitch SB, Bikoff EK, Unanue ER. Immunity 20 467-476 (2004)
  84. Human CD4+ T-cell epitope repertoire on the C2 domain of coagulation factor VIII. Reding MT, Okita DK, Diethelm-Okita BM, Anderson TA, Conti-Fine BM. J. Thromb. Haemost. 1 1777-1784 (2003)
  85. Crystal structure of a superantigen bound to MHC class II displays zinc and peptide dependence. Petersson K, Håkansson M, Nilsson H, Forsberg G, Svensson LA, Liljas A, Walse B. EMBO J. 20 3306-3312 (2001)
  86. HLA-DM targets the hydrogen bond between the histidine at position beta81 and peptide to dissociate HLA-DR-peptide complexes. Narayan K, Chou CL, Kim A, Hartman IZ, Dalai S, Khoruzhenko S, Sadegh-Nasseri S. Nat. Immunol. 8 92-100 (2007)
  87. A Shannon entropy analysis of immunoglobulin and T cell receptor. Stewart JJ, Lee CY, Ibrahim S, Watts P, Shlomchik M, Weigert M, Litwin S. Mol. Immunol. 34 1067-1082 (1997)
  88. Crystal structure of HLA-DP2 and implications for chronic beryllium disease. Dai S, Murphy GA, Crawford F, Mack DG, Falta MT, Marrack P, Kappler JW, Fontenot AP. Proc. Natl. Acad. Sci. U.S.A. 107 7425-7430 (2010)
  89. Shapes of MHC restriction. Garboczi DN, Biddison WE. Immunity 10 1-7 (1999)
  90. HLA-DM captures partially empty HLA-DR molecules for catalyzed removal of peptide. Anders AK, Call MJ, Schulze MS, Fowler KD, Schubert DA, Seth NP, Sundberg EJ, Wucherpfennig KW. Nat. Immunol. 12 54-61 (2011)
  91. Differences in the risk of celiac disease associated with HLA-DQ2.5 or HLA-DQ2.2 are related to sustained gluten antigen presentation. Fallang LE, Bergseng E, Hotta K, Berg-Larsen A, Kim CY, Sollid LM. Nat. Immunol. 10 1096-1101 (2009)
  92. T cell responses to a human cartilage autoantigen in the context of rheumatoid arthritis-associated and nonassociated HLA-DR4 alleles. Cope AP, Patel SD, Hall F, Congia M, Hubers HA, Verheijden GF, Boots AM, Menon R, Trucco M, Rijnders AW, Sønderstrup G. Arthritis Rheum. 42 1497-1507 (1999)
  93. Three-dimensional structure analysis of PROSITE patterns. Kasuya A, Thornton JM. J. Mol. Biol. 286 1673-1691 (1999)
  94. Heterogeneity of rheumatoid arthritis: from phenotypes to genotypes. Weyand CM, Klimiuk PA, Goronzy JJ. Springer Semin. Immunopathol. 20 5-22 (1998)
  95. Identification of a promiscuous T-cell epitope in Mycobacterium tuberculosis Mce proteins. Panigada M, Sturniolo T, Besozzi G, Boccieri MG, Sinigaglia F, Grassi GG, Grassi F. Infect. Immun. 70 79-85 (2002)
  96. Crystal structure of the HLA-DM-HLA-DR1 complex defines mechanisms for rapid peptide selection. Pos W, Sethi DK, Call MJ, Schulze MS, Anders AK, Pyrdol J, Wucherpfennig KW. Cell 151 1557-1568 (2012)
  97. Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. Donaldson PT, Daly AK, Henderson J, Graham J, Pirmohamed M, Bernal W, Day CP, Aithal GP. J. Hepatol. 53 1049-1053 (2010)
  98. Giant cell vasculitis is a T cell-dependent disease. Brack A, Geisler A, Martinez-Taboada VM, Younge BR, Goronzy JJ, Weyand CM. Mol. Med. 3 530-543 (1997)
  99. The structural basis of MHC control of collagen-induced arthritis; binding of the immunodominant type II collagen 256-270 glycopeptide to H-2Aq and H-2Ap molecules. Kjellén P, Brunsberg U, Broddefalk J, Hansen B, Vestberg M, Ivarsson I, Engström A, Svejgaard A, Kihlberg J, Fugger L, Holmdahl R. Eur. J. Immunol. 28 755-767 (1998)
  100. Influence of shared epitope-negative HLA-DRB1 alleles on genetic susceptibility to rheumatoid arthritis. Reviron D, Perdriger A, Toussirot E, Wendling D, Balandraud N, Guis S, Semana G, Tiberghien P, Mercier P, Roudier J. Arthritis Rheum. 44 535-540 (2001)
  101. A new categorization of HLA DR alleles on a functional basis. Ou D, Mitchell LA, Tingle AJ. Hum. Immunol. 59 665-676 (1998)
  102. A basis for alloreactivity: MHC helical residues broaden peptide recognition by the TCR. Daniel C, Horvath S, Allen PM. Immunity 8 543-552 (1998)
  103. Binding of outer surface protein A and human lymphocyte function-associated antigen 1 peptides to HLA-DR molecules associated with antibiotic treatment-resistant Lyme arthritis. Steere AC, Falk B, Drouin EE, Baxter-Lowe LA, Hammer J, Nepom GT. Arthritis Rheum. 48 534-540 (2003)
  104. Similar antigenic surfaces, rather than sequence homology, dictate T-cell epitope molecular mimicry. Quaratino S, Thorpe CJ, Travers PJ, Londei M. Proc. Natl. Acad. Sci. U.S.A. 92 10398-10402 (1995)
  105. Alternate interactions define the binding of peptides to the MHC molecule IA(b). Liu X, Dai S, Crawford F, Fruge R, Marrack P, Kappler J. Proc. Natl. Acad. Sci. U.S.A. 99 8820-8825 (2002)
  106. Single amino acid substitutions on a Japanese cedar pollen allergen (Cry j 1)-derived peptide induced alterations in human T cell responses and T cell receptor antagonism. Ikagawa S, Matsushita S, Chen YZ, Ishikawa T, Nishimura Y. J. Allergy Clin. Immunol. 97 53-64 (1996)
  107. Model for the peptide-free conformation of class II MHC proteins. Painter CA, Cruz A, López GE, Stern LJ, Zavala-Ruiz Z. PLoS ONE 3 e2403 (2008)
  108. Fluorogenic probes for monitoring peptide binding to class II MHC proteins in living cells. Venkatraman P, Nguyen TT, Sainlos M, Bilsel O, Chitta S, Imperiali B, Stern LJ. Nat. Chem. Biol. 3 222-228 (2007)
  109. Modeling the structure of bound peptide ligands to major histocompatibility complex. Tong JC, Tan TW, Ranganathan S. Protein Sci. 13 2523-2532 (2004)
  110. Hidden Markov model-based prediction of antigenic peptides that interact with MHC class II molecules. Noguchi H, Kato R, Hanai T, Matsubara Y, Honda H, Brusic V, Kobayashi T. J. Biosci. Bioeng. 94 264-270 (2002)
  111. Genetic risk factors in inflammatory abdominal aortic aneurysms: polymorphic residue 70 in the HLA-DR B1 gene as a key genetic element. Rasmussen TE, Hallett JW, Metzger RL, Richardson DM, Harmsen WS, Goronzy JJ, Weyand CM. J. Vasc. Surg. 25 356-364 (1997)
  112. Susceptibility to anti-glomerular basement membrane disease is strongly associated with HLA-DRB1 genes. Fisher M, Pusey CD, Vaughan RW, Rees AJ. Kidney Int. 51 222-229 (1997)
  113. Critical contribution of beta chain residue 57 in peptide binding ability of both HLA-DR and -DQ molecules. Nepom BS, Nepom GT, Coleman M, Kwok WW. Proc. Natl. Acad. Sci. U.S.A. 93 7202-7206 (1996)
  114. Selection of a single amino acid substitution in the hemagglutinin molecule by chicken eggs can render influenza A virus (H3) candidate vaccine ineffective. Kodihalli S, Justewicz DM, Gubareva LV, Webster RG. J. Virol. 69 4888-4897 (1995)
  115. Human leukocyte antigen-DRB1 position 11 residues are a common protective marker for sarcoidosis. Foley PJ, McGrath DS, Puscinska E, Petrek M, Kolek V, Drabek J, Lympany PA, Pantelidis P, Welsh KI, Zielinski J, du Bois RM. Am. J. Respir. Cell Mol. Biol. 25 272-277 (2001)
  116. HIV-1 variation diminishes CD4 T lymphocyte recognition. Harcourt GC, Garrard S, Davenport MP, Edwards A, Phillips RE. J. Exp. Med. 188 1785-1793 (1998)
  117. Identification and characterization of the viral interaction determinant of the subgroup A avian leukosis virus receptor. Zingler K, Bélanger Ca, Peters R, Agard E, Young JA. J. Virol. 69 4261-4266 (1995)
  118. Allelic differences affecting invariant chain dependency of MHC class II subunit assembly. Bikoff EK, Germain RN, Robertson EJ. Immunity 2 301-310 (1995)
  119. Flexibility of the MHC class II peptide binding cleft in the bound, partially filled, and empty states: a molecular dynamics simulation study. Yaneva R, Springer S, Zacharias M. Biopolymers 91 14-27 (2009)
  120. Functional mapping of protective domains and epitopes in the rotavirus VP6 protein. Choi AH, Basu M, McNeal MM, Flint J, VanCott JL, Clements JD, Ward RL. J. Virol. 74 11574-11580 (2000)
  121. Susceptibility to human papillomavirus-associated cervical intra-epithelial neoplasia is determined by specific HLA DR-DQ alleles. Odunsi K, Terry G, Ho L, Bell J, Cuzick J, Ganesan TS. Int. J. Cancer 67 595-602 (1996)
  122. A structural transition in class II major histocompatibility complex proteins at mildly acidic pH. Runnels HA, Moore JC, Jensen PE. J. Exp. Med. 183 127-136 (1996)
  123. Five HLA-DP molecules frequently expressed in the worldwide human population share a common HLA supertypic binding specificity. Sidney J, Steen A, Moore C, Ngo S, Chung J, Peters B, Sette A. J. Immunol. 184 2492-2503 (2010)
  124. Design, engineering and production of functional single-chain T cell receptor ligands. Burrows GG, Chang JW, Bächinger HP, Bourdette DN, Offner H, Vandenbark AA. Protein Eng. 12 771-778 (1999)
  125. Long-term survival of a urodele amphibian despite depleted major histocompatibility complex variation. Babik W, Pabijan M, Arntzen JW, Cogâlniceanu D, Durka W, Radwan J. Mol. Ecol. 18 769-781 (2009)
  126. Strong positive selection and habitat-specific amino acid substitution patterns in MHC from an estuarine fish under intense pollution stress. Cohen S. Mol. Biol. Evol. 19 1870-1880 (2002)
  127. Influence of HLA-DR phenotype on the risk of hepatitis C virus-associated mixed cryoglobulinemia. Cacoub P, Renou C, Kerr G, Hüe S, Rosenthal E, Cohen P, Kaplanski G, Charlotte F, Thibault V, Ghillani P, Piette JC, Caillat-Zucman S. Arthritis Rheum. 44 2118-2124 (2001)
  128. Analysis of HLA haplotypes in autoimmune hepatitis type 1: identifying the major susceptibility locus. Goldberg AC, Bittencourt PL, Mougin B, Cançado EL, Porta G, Carrilho F, Kalil J. Hum. Immunol. 62 165-169 (2001)
  129. MhcDRB-sequences from cynomolgus macaques (Macaca fascicularis) of different origin. Leuchte N, Berry N, Köhler B, Almond N, LeGrand R, Thorstensson R, Titti F, Sauermann U. Tissue Antigens 63 529-537 (2004)
  130. The rsp5-domain is shared by proteins of diverse functions. Hofmann K, Bucher P. FEBS Lett. 358 153-157 (1995)
  131. Human CD4+ T cell epitopes from vaccinia virus induced by vaccination or infection. Calvo-Calle JM, Strug I, Nastke MD, Baker SP, Stern LJ. PLoS Pathog. 3 1511-1529 (2007)
  132. The influence of major histocompatibility complex class II genes and T-cell Vbeta repertoire on response to immunization with HBsAg. Höhler T, Meyer CU, Notghi A, Stradmann-Bellinghausen B, Schneider PM, Starke R, Zepp F, Sänger R, Clemens R, Meyer zum Büschenfelde KH, Rittner C. Hum. Immunol. 59 212-218 (1998)
  133. pH-dependent peptide binding properties of the type I diabetes-associated I-Ag7 molecule: rapid release of CLIP at an endosomal pH. Hausmann DH, Yu B, Hausmann S, Wucherpfennig KW. J. Exp. Med. 189 1723-1734 (1999)
  134. Binding of a soluble alpha beta T-cell receptor to superantigen/major histocompatibility complex ligands. Kappler J, White J, Kozono H, Clements J, Marrack P. Proc. Natl. Acad. Sci. U.S.A. 91 8462-8466 (1994)
  135. Complementarity and redundancy of the binding specificity of HLA-DRB1, -DRB3, -DRB4 and -DRB5 molecules. Texier C, Pouvelle-Moratille S, Busson M, Charron D, Ménez A, Maillère B. Eur. J. Immunol. 31 1837-1846 (2001)
  136. Motifs and supermotifs for MHC class II binding peptides. Sinigaglia F, Hammer J. J. Exp. Med. 181 449-451 (1995)
  137. HLA-DRB1 alleles and Jk(a) immunization. Reviron D, Dettori I, Ferrera V, Legrand D, Touinssi M, Mercier P, de Micco P, Chiaroni J. Transfusion 45 956-959 (2005)
  138. The major histocompatibility class II alpha chain in salmonid fishes. Grimholt U, Getahun A, Hermsen T, Stet RJ. Dev. Comp. Immunol. 24 751-763 (2000)
  139. Three-dimensional structure of H-2Dd complexed with an immunodominant peptide from human immunodeficiency virus envelope glycoprotein 120. Li H, Natarajan K, Malchiodi EL, Margulies DH, Mariuzza RA. J. Mol. Biol. 283 179-191 (1998)
  140. New ligands binding to the human leukocyte antigen class II molecule DRB1*0101 based on the activity pattern of an undecapeptide library. Fleckenstein B, Kalbacher H, Muller CP, Stoll D, Halder T, Jung G, Wiesmüller KH. Eur. J. Biochem. 240 71-77 (1996)
  141. Evidence for a conformational change in a class II major histocompatibility complex molecule occurring in the same pH range where antigen binding is enhanced. Boniface JJ, Lyons DS, Wettstein DA, Allbritton NL, Davis MM. J. Exp. Med. 183 119-126 (1996)
  142. Early biochemical signals arise from low affinity TCR-ligand reactions at the cell-cell interface. Beeson C, Rabinowitz J, Tate K, Gütgemann I, Chien YH, Jones PP, Davis MM, McConnell HM. J. Exp. Med. 184 777-782 (1996)
  143. Natural peptides isolated from Gly86/Val86-containing variants of HLA-DR1, -DR11, -DR13, and -DR52. Verreck FA, van de Poel A, Drijfhout JW, Amons R, Coligan JE, Konig F. Immunogenetics 43 392-397 (1996)
  144. Structural basis of the abscess-modulating polysaccharide A2 from Bacteroides fragilis. Wang Y, Kalka-Moll WM, Roehrl MH, Kasper DL. Proc. Natl. Acad. Sci. U.S.A. 97 13478-13483 (2000)
  145. Pemphigus vulgaris autoantibody response is linked to HLA-DQB1*0503 in Pakistani patients. Delgado JC, Hameed A, Yunis JJ, Bhol K, Rojas AI, Rehman SB, Khan AA, Ahmad M, Alper CA, Ahmed AR, Yunis EJ. Hum. Immunol. 57 110-119 (1997)
  146. Superactivation of an immune response triggered by oligomerized T cell epitopes. Rötzschke O, Falk K, Strominger JL. Proc. Natl. Acad. Sci. U.S.A. 94 14642-14647 (1997)
  147. Distinct intracellular compartments involved in invariant chain degradation and antigenic peptide loading of major histocompatibility complex (MHC) class II molecules. Ferrari G, Knight AM, Watts C, Pieters J. J. Cell Biol. 139 1433-1446 (1997)
  148. Quantitative analysis of peptides from myelin basic protein binding to the MHC class II protein, I-Au, which confers susceptibility to experimental allergic encephalomyelitis. Fugger L, Liang J, Gautam A, Rothbard JB, McDevitt HO. Mol. Med. 2 181-188 (1996)
  149. Major histocompatibility complex DRB1 gene: its role in nematode resistance in Suffolk and Texel sheep breeds. Sayers G, Good B, Hanrahan JP, Ryan M, Angles JM, Sweeney T. Parasitology 131 403-409 (2005)
  150. Epitope repertoire of human CD4(+) T cells on the A3 domain of coagulation factor VIII. Reding MT, Okita DK, Diethelm-Okita BM, Anderson TA, Conti-Fine BM. J. Thromb. Haemost. 2 1385-1394 (2004)
  151. Empty class II major histocompatibility complex created by peptide photolysis establishes the role of DM in peptide association. Grotenbreg GM, Nicholson MJ, Fowler KD, Wilbuer K, Octavio L, Yang M, Chakraborty AK, Ploegh HL, Wucherpfennig KW. J. Biol. Chem. 282 21425-21436 (2007)
  152. Distribution of HLA class II alleles among Spanish patients with pemphigus vulgaris. González-Escribano MF, Jiménez G, Walter K, Montes M, Perez-Bernal AM, Rodríguez MR, Conejo-Mir JS, Núñez-Roldán A. Tissue Antigens 52 275-278 (1998)
  153. Antigen processing and presentation of a naturally glycosylated protein elicits major histocompatibility complex class II-restricted, carbohydrate-specific T cells. Michaëlsson E, Broddefalk J, Engström A, Kihlberg J, Holmdahl R. Eur. J. Immunol. 26 1906-1910 (1996)
  154. T-cell responses to outer membrane proteins of Neisseria meningitidis: comparative study of the Opa, Opc, and PorA proteins. Wiertz EJ, Delvig A, Donders EM, Brugghe HF, van Unen LM, Timmermans HA, Achtman M, Hoogerhout P, Poolman JT. Infect. Immun. 64 298-304 (1996)
  155. Association of BLV infection profiles with alleles of the BoLA-DRB3.2 gene. Juliarena MA, Poli M, Sala L, Ceriani C, Gutierrez S, Dolcini G, Rodríguez EM, Mariño B, Rodríguez-Dubra C, Esteban EN. Anim. Genet. 39 432-438 (2008)
  156. Characteristics of carbohydrate antigen binding to the presentation protein HLA-DR. Cobb BA, Kasper DL. Glycobiology 18 707-718 (2008)
  157. Meta-analysis of HLA-DRB1 and HLA-DQB1 polymorphisms in Latin American patients with systemic lupus erythematosus. Castaño-Rodríguez N, Diaz-Gallo LM, Pineda-Tamayo R, Rojas-Villarraga A, Anaya JM. Autoimmun Rev 7 322-330 (2008)
  158. Beryllium binding to HLA-DP molecule carrying the marker of susceptibility to berylliosis glutamate beta 69. Amicosante M, Sanarico N, Berretta F, Arroyo J, Lombardi G, Lechler R, Colizzi V, Saltini C. Hum. Immunol. 62 686-693 (2001)
  159. A roadmap for HLA-DR peptide binding specificities. Chelvanayagam G. Hum. Immunol. 58 61-69 (1997)
  160. Cutting edge: HLA-DM functions through a mechanism that does not require specific conserved hydrogen bonds in class II MHC-peptide complexes. Zhou Z, Callaway KA, Weber DA, Jensen PE. J. Immunol. 183 4187-4191 (2009)
  161. Population fragmentation and major histocompatibility complex variation in the spotted suslik, Spermophilus suslicus. Biedrzycka A, Radwan J. Mol. Ecol. 17 4801-4811 (2008)
  162. Diversifying and purifying selection in the peptide binding region of DRB in mammals. Furlong RF, Yang Z. J. Mol. Evol. 66 384-394 (2008)
  163. A hairpin turn in a class II MHC-bound peptide orients residues outside the binding groove for T cell recognition. Zavala-Ruiz Z, Strug I, Walker BD, Norris PJ, Stern LJ. Proc. Natl. Acad. Sci. U.S.A. 101 13279-13284 (2004)
  164. Directed evolution of soluble single-chain human class II MHC molecules. Esteban O, Zhao H. J. Mol. Biol. 340 81-95 (2004)
  165. NMR identification of left-handed polyproline type II helices. Lam SL, Hsu VL. Biopolymers 69 270-281 (2003)
  166. Insights into autoimmunity gained from structural analysis of MHC-peptide complexes. Wucherpfennig KW. Curr. Opin. Immunol. 13 650-656 (2001)
  167. Influence of HLA-DR on the phenotype of CD4+ T lymphocytes specific for an epitope of the 16-kDa alpha-crystallin antigen of Mycobacterium tuberculosis. Agrewala JN, Wilkinson RJ. Eur. J. Immunol. 29 1753-1761 (1999)
  168. Differential thymic selection outcomes stimulated by focal structural alteration in peptide/major histocompatibility complex ligands. Ghendler Y, Teng MK, Liu JH, Witte T, Liu J, Kim KS, Kern P, Chang HC, Wang JH, Reinherz EL. Proc. Natl. Acad. Sci. U.S.A. 95 10061-10066 (1998)
  169. Kinetic intermediates in the reactions between peptides and proteins of major histocompatibility complex class II. Beeson C, McConnell HM. Proc. Natl. Acad. Sci. U.S.A. 91 8842-8845 (1994)
  170. Pyrrolinone-based peptidomimetics. "Let the enzyme or receptor be the judge". Smith AB, Charnley AK, Hirschmann R. Acc. Chem. Res. 44 180-193 (2011)
  171. Toward an atomistic understanding of the immune synapse: large-scale molecular dynamics simulation of a membrane-embedded TCR-pMHC-CD4 complex. Wan S, Flower DR, Coveney PV. Mol. Immunol. 45 1221-1230 (2008)
  172. Alteration at a single amino acid residue in the T cell receptor alpha chain complementarity determining region 2 changes the differentiation of naive CD4 T cells in response to antigen from T helper cell type 1 (Th1) to Th2. Blander JM, Sant'Angelo DB, Bottomly K, Janeway CA. J. Exp. Med. 191 2065-2074 (2000)
  173. Structural basis of cytochrome c presentation by IE(k). Fremont DH, Dai S, Chiang H, Crawford F, Marrack P, Kappler J. J. Exp. Med. 195 1043-1052 (2002)
  174. MHC diversity in bottlenecked populations: a simulation model Ejsmond MJ, Radwan J. Conserv. Genet. 12 129-137 (2011)
  175. HLA and alveolar echinococcosis. Eiermann TH, Bettens F, Tiberghien P, Schmitz K, Beurton I, Bresson-Hadni S, Ammann RW, Goldmann SF, Vuitton DA, Gottstein B, Kern P. Tissue Antigens 52 124-129 (1998)
  176. DR4 subtypes and their molecular properties in a population-based study of Swedish childhood diabetes. Sanjeevi CB, Höök P, Landin-Olsson M, Kockum I, Dahlquist G, Lybrand TP, Lernmark A. Tissue Antigens 47 275-283 (1996)
  177. Structural features of the invariant chain fragment CLIP controlling rapid release from HLA-DR molecules and inhibition of peptide binding. Kropshofer H, Vogt AB, Hämmerling GJ. Proc. Natl. Acad. Sci. U.S.A. 92 8313-8317 (1995)
  178. Divergent motifs but overlapping binding repertoires of six HLA-DQ molecules frequently expressed in the worldwide human population. Sidney J, Steen A, Moore C, Ngo S, Chung J, Peters B, Sette A. J. Immunol. 185 4189-4198 (2010)
  179. Functional categorization of HLA-DRB1 alleles in rheumatoid arthritis: the protective effect. Gibert M, Balandraud N, Touinssi M, Mercier P, Roudier J, Reviron D. Hum. Immunol. 64 930-935 (2003)
  180. Conserved water molecules in MHC class-I molecules and their putative structural and functional roles. Ogata K, Wodak SJ. Protein Eng. 15 697-705 (2002)
  181. Patterns of variability at the major histocompatibility class II alpha locus in Atlantic salmon contrast with those at the class I locus. Consuegra S, Megens HJ, Leon K, Stet RJ, Jordan WC. Immunogenetics 57 16-24 (2005)
  182. Interaction of MHC class II molecules with the invariant chain: role of the invariant chain (81-90) region. Stumptner P, Benaroch P. EMBO J. 16 5807-5818 (1997)
  183. Efficient loading of HLA-DR with a T helper epitope by genetic exchange of CLIP. van Bergen J, Schoenberger SP, Verreck F, Amons R, Offringa R, Koning F. Proc. Natl. Acad. Sci. U.S.A. 94 7499-7502 (1997)
  184. A general model of invariant chain association with class II major histocompatibility complex proteins. Lee C, McConnell HM. Proc. Natl. Acad. Sci. U.S.A. 92 8269-8273 (1995)
  185. State of the art and challenges in sequence based T-cell epitope prediction. Lundegaard C, Hoof I, Lund O, Nielsen M. Immunome Res 6 Suppl 2 S3 (2010)
  186. A xenon-129 biosensor for monitoring MHC-peptide interactions. Schlundt A, Kilian W, Beyermann M, Sticht J, Günther S, Höpner S, Falk K, Roetzschke O, Mitschang L, Freund C. Angew. Chem. Int. Ed. Engl. 48 4142-4145 (2009)
  187. Owl monkey MHC-DRB exon 2 reveals high similarity with several HLA-DRB lineages. Suárez CF, Patarroyo ME, Trujillo E, Estupiñán M, Baquero JE, Parra C, Rodriguez R. Immunogenetics 58 542-558 (2006)
  188. A diverse set of oligomeric class II MHC-peptide complexes for probing T-cell receptor interactions. Cochran JR, Stern LJ. Chem. Biol. 7 683-696 (2000)
  189. Evidence that the autoimmune antigen myelin basic protein (MBP) Ac1-9 binds towards one end of the major histocompatibility complex (MHC) cleft. Lee C, Liang MN, Tate KM, Rabinowitz JD, Beeson C, Jones PP, McConnell HM. J. Exp. Med. 187 1505-1516 (1998)
  190. HLA Class II genotypes associated with early-onset periodontitis: DQB1 molecule primarily confers susceptibility to the disease. Ohyama H, Takashiba S, Oyaizu K, Nagai A, Naruse T, Inoko H, Kurihara H, Murayama Y. J. Periodontol. 67 888-894 (1996)
  191. Structure of human T-cell receptors specific for an immunodominant myelin basic protein peptide: positioning of T-cell receptors on HLA-DR2/peptide complexes. Wucherpfennig KW, Hafler DA, Strominger JL. Proc. Natl. Acad. Sci. U.S.A. 92 8896-8900 (1995)
  192. Polymorphisms in MHC-DRA and -DRB alleles of water buffalo (Bubalus bubalis) reveal different features from cattle DR alleles. Sena L, Schneider MP, Brenig B, Honeycutt RL, Womack JE, Skow LC. Anim. Genet. 34 1-10 (2003)
  193. A pH-sensitive histidine residue as control element for ligand release from HLA-DR molecules. Rötzschke O, Lau JM, Hofstätter M, Falk K, Strominger JL. Proc. Natl. Acad. Sci. U.S.A. 99 16946-16950 (2002)
  194. Energetics and cooperativity of the hydrogen bonding and anchor interactions that bind peptides to MHC class II protein. McFarland BJ, Katz JF, Sant AJ, Beeson C. J. Mol. Biol. 350 170-183 (2005)
  195. Topology of T cell receptor-peptide/class I MHC interaction defined by charge reversal complementation and functional analysis. Chang HC, Smolyar A, Spoerl R, Witte T, Yao Y, Goyarts EC, Nathenson SG, Reinherz EL. J. Mol. Biol. 271 278-293 (1997)
  196. T-cell epitope analysis using subtracted expression libraries (TEASEL): application to a 38-kDA autoantigen recognized by T cells from an insulin-dependent diabetic patient. Neophytou PI, Roep BO, Arden SD, Muir EM, Duinkerken G, Kallan A, de Vries RR, Hutton JC. Proc. Natl. Acad. Sci. U.S.A. 93 2014-2018 (1996)
  197. Binding of an invariant-chain peptide, CLIP, to I-A major histocompatibility complex class II molecules. Gautam AM, Pearson C, Quinn V, McDevitt HO, Milburn PJ. Proc. Natl. Acad. Sci. U.S.A. 92 335-339 (1995)
  198. Genome-wide association study identifies five susceptibility loci for follicular lymphoma outside the HLA region. Skibola CF, Berndt SI, Vijai J, Conde L, Wang Z, Yeager M, de Bakker PI, Birmann BM, Vajdic CM, Foo JN, Bracci PM, Vermeulen RC, Slager SL, de Sanjose S, Wang SS, Linet MS, Salles G, Lan Q, Severi G, Hjalgrim H, Lightfoot T, Melbye M, Gu J, Ghesquières H, Link BK, Morton LM, Holly EA, Smith A, Tinker LF, Teras LR, Kricker A, Becker N, Purdue MP, Spinelli JJ, Zhang Y, Giles GG, Vineis P, Monnereau A, Bertrand KA, Albanes D, Zeleniuch-Jacquotte A, Gabbas A, Chung CC, Burdett L, Hutchinson A, Lawrence C, Montalvan R, Liang L, Huang J, Ma B, Liu J, Adami HO, Glimelius B, Ye Y, Nowakowski GS, Dogan A, Thompson CA, Habermann TM, Novak AJ, Liebow M, Witzig TE, Weiner GJ, Schenk M, Hartge P, De Roos AJ, Cozen W, Zhi D, Akers NK, Riby J, Smith MT, Lacher M, Villano DJ, Maria A, Roman E, Kane E, Jackson RD, North KE, Diver WR, Turner J, Armstrong BK, Benavente Y, Boffetta P, Brennan P, Foretova L, Maynadie M, Staines A, McKay J, Brooks-Wilson AR, Zheng T, Holford TR, Chamosa S, Kaaks R, Kelly RS, Ohlsson B, Travis RC, Weiderpass E, Clavel J, Giovannucci E, Kraft P, Virtamo J, Mazza P, Cocco P, Ennas MG, Chiu BC, Fraumeni JF, Nieters A, Offit K, Wu X, Cerhan JR, Smedby KE, Chanock SJ, Rothman N. Am. J. Hum. Genet. 95 462-471 (2014)
  199. HLA-DM constrains epitope selection in the human CD4 T cell response to vaccinia virus by favoring the presentation of peptides with longer HLA-DM-mediated half-lives. Yin L, Calvo-Calle JM, Dominguez-Amorocho O, Stern LJ. J. Immunol. 189 3983-3994 (2012)
  200. HLA-DR-restricted T-cell responses to factor VIII epitopes in a mild haemophilia A family with missense substitution A2201P. Ettinger RA, James EA, Kwok WW, Thompson AR, Pratt KP. Haemophilia 16 44-55 (2010)
  201. In vivo enhancement of peptide display by MHC class II molecules with small molecule catalysts of peptide exchange. Call MJ, Xing X, Cuny GD, Seth NP, Altmann DM, Fugger L, Krogsgaard M, Stein RL, Wucherpfennig KW. J. Immunol. 182 6342-6352 (2009)
  202. Trans-species polymorphism of the Mhc class II DRB-like gene in banded penguins (genus Spheniscus). Kikkawa EF, Tsuda TT, Sumiyama D, Naruse TK, Fukuda M, Kurita M, Wilson RP, LeMaho Y, Miller GD, Tsuda M, Murata K, Kulski JK, Inoko H. Immunogenetics 61 341-352 (2009)
  203. Ovine progressive pneumonia provirus levels associate with breed and Ovar-DRB1. Herrmann-Hoesing LM, White SN, Mousel MR, Lewis GS, Knowles DP. Immunogenetics 60 749-758 (2008)
  204. Polymorphism, haplotype composition, and selection in the Mhc-DRB of wild baboons. Huchard E, Weill M, Cowlishaw G, Raymond M, Knapp LA. Immunogenetics 60 585-598 (2008)
  205. The shared epitope hypothesis in rheumatoid arthritis: evaluation of alternative classification criteria in a large UK Caucasian cohort. Morgan AW, Haroon-Rashid L, Martin SG, Gooi HC, Worthington J, Thomson W, Barrett JH, Emery P. Arthritis Rheum. 58 1275-1283 (2008)
  206. Anchor side chains of short peptide fragments trigger ligand-exchange of class II MHC molecules. Gupta S, Höpner S, Rupp B, Günther S, Dickhaut K, Agarwal N, Cardoso MC, Kühne R, Wiesmüller KH, Jung G, Falk K, Rötzschke O. PLoS ONE 3 e1814 (2008)
  207. Adaptive evolution of multiple-variable exons and structural diversity of drug-metabolizing enzymes. Li C, Wu Q. BMC Evol. Biol. 7 69 (2007)
  208. Molecular characterization of MHC class II in a nonmodel anuran species, the fire-bellied toad Bombina bombina. Hauswaldt JS, Stuckas H, Pfautsch S, Tiedemann R. Immunogenetics 59 479-491 (2007)
  209. Crystal structure of staphylococcal enterotoxin I (SEI) in complex with a human major histocompatibility complex class II molecule. Fernández MM, Guan R, Swaminathan CP, Malchiodi EL, Mariuzza RA. J. Biol. Chem. 281 25356-25364 (2006)
  210. HLA-DRB1 polymorphism is associated with Kell immunisation. Chiaroni J, Dettori I, Ferrera V, Legrand D, Touinssi M, Mercier P, de Micco P, Reviron D. Br. J. Haematol. 132 374-378 (2006)
  211. The influence of ovine MHC class II DRB1 alleles on immune response in bovine leukemia virus infection. Konnai S, Takeshima SN, Tajima S, Yin SA, Okada K, Onuma M, Aida Y. Microbiol. Immunol. 47 223-232 (2003)
  212. Synthetic amino acid copolymers that bind to HLA-DR proteins and inhibit type II collagen-reactive T cell clones. Fridkis-Hareli M, Rosloniec EF, Fugger L, Strominger JL. Proc. Natl. Acad. Sci. U.S.A. 95 12528-12531 (1998)
  213. Analysis of the primary T-cell response to Sendai virus infection in C57BL/6 mice: CD4+ T-cell recognition is directed predominantly to the hemagglutinin-neuraminidase glycoprotein. Cole GA, Katz JM, Hogg TL, Ryan KW, Portner A, Woodland DL. J. Virol. 68 6863-6870 (1994)
  214. Comparison of peptide-major histocompatibility complex tetramers and dextramers for the identification of antigen-specific T cells. Dolton G, Lissina A, Skowera A, Ladell K, Tungatt K, Jones E, Kronenberg-Versteeg D, Akpovwa H, Pentier JM, Holland CJ, Godkin AJ, Cole DK, Neller MA, Miles JJ, Price DA, Peakman M, Sewell AK. Clin. Exp. Immunol. 177 47-63 (2014)
  215. Crystallographic structure of the human leukocyte antigen DRA, DRB3*0101: models of a directional alloimmune response and autoimmunity. Parry CS, Gorski J, Stern LJ. J. Mol. Biol. 371 435-446 (2007)
  216. Identification of destabilizing residues in HLA class II-selected bacteriophage display libraries edited by HLA-DM. Raddrizzani L, Bono E, Vogt AB, Kropshofer H, Gallazzi F, Sturniolo T, Hämmerling GJ, Sinigaglia F, Hammer J. Eur. J. Immunol. 29 660-668 (1999)
  217. Expression and crystallization of the complex of HLA-DR2 (DRA, DRB1*1501) and an immunodominant peptide of human myelin basic protein. Gauthier L, Smith KJ, Pyrdol J, Kalandadze A, Strominger JL, Wiley DC, Wucherpfennig KW. Proc. Natl. Acad. Sci. U.S.A. 95 11828-11833 (1998)
  218. A generic method for expression and use of "tagged" soluble versions of cell surface receptors. Whitehorn EA, Tate E, Yanofsky SD, Kochersperger L, Davis A, Mortensen RB, Yonkovich S, Bell K, Dower WJ, Barrett RW. Biotechnology (N.Y.) 13 1215-1219 (1995)
  219. A hemagglutinin-based multipeptide construct elicits enhanced protective immune response in mice against influenza A virus infection. Horváth A, Tóth GK, Gogolák P, Nagy Z, Kurucz I, Pecht I, Rajnavölgyi E. Immunol. Lett. 60 127-136 (1998)
  220. Lack of association of HLA-DRB1 genotype with radiologic progression in Japanese patients with early rheumatoid arthritis. Higami K, Hakoda M, Matsuda Y, Ueda H, Kashiwazaki S. Arthritis Rheum. 40 2241-2247 (1997)
  221. Binding of soluble natural ligands to a soluble human T-cell receptor fragment produced in Escherichia coli. Hilyard KL, Reyburn H, Chung S, Bell JI, Strominger JL. Proc. Natl. Acad. Sci. U.S.A. 91 9057-9061 (1994)
  222. Soluble mouse major histocompatibility complex class II molecules produced in Drosophila cells. Wallny HJ, Sollami G, Karjalainen K. Eur. J. Immunol. 25 1262-1266 (1995)
  223. Amino acid position 11 of HLA-DRβ1 is a major determinant of chromosome 6p association with ulcerative colitis. Achkar JP, Klei L, de Bakker PI, Bellone G, Rebert N, Scott R, Lu Y, Regueiro M, Brzezinski A, Kamboh MI, Fiocchi C, Devlin B, Trucco M, Ringquist S, Roeder K, Duerr RH. Genes Immun. 13 245-252 (2012)
  224. T cell recognition of the A2 domain of coagulation factor VIII in hemophilia patients and healthy subjects. Hu GL, Okita DK, Conti-Fine BM. J. Thromb. Haemost. 2 1908-1917 (2004)
  225. Crystal structure of a SEA variant in complex with MHC class II reveals the ability of SEA to crosslink MHC molecules. Petersson K, Thunnissen M, Forsberg G, Walse B. Structure 10 1619-1626 (2002)
  226. A proposed model for the PEX5-peroxisomal targeting signal-1 recognition complex. Gatto GJ, Geisbrecht BV, Gould SJ, Berg JM. Proteins 38 241-246 (2000)
  227. Specific and general HLA-DR binding motifs: comparison of algorithms. Borrás-Cuesta F, Golvano J, García-Granero M, Sarobe P, Riezu-Boj J, Huarte E, Lasarte J. Hum. Immunol. 61 266-278 (2000)
  228. Analysis of T-cell reactive regions and HLA-DR4 binding motifs on the latex allergen Hev b 1 (rubber elongation factor). Raulf-Heimsoth M, Chen Z, Rihs HP, Kalbacher H, Liebers V, Baur X. Clin. Exp. Allergy 28 339-348 (1998)
  229. Epitopes for human CD4+ cells on diphtheria toxin: structural features of sequence segments forming epitopes recognized by most subjects. Raju R, Navaneetham D, Okita D, Diethelm-Okita B, McCormick D, Conti-Fine BM. Eur. J. Immunol. 25 3207-3214 (1995)
  230. BoLA-DR peptide binding pockets are fundamental for foot-and-mouth disease virus vaccine design in cattle. Baxter R, Craigmile SC, Haley C, Douglas AJ, Williams JL, Glass EJ. Vaccine 28 28-37 (2009)
  231. HLA-DM mediates epitope selection by a "compare-exchange" mechanism when a potential peptide pool is available. Ferrante A, Anderson MW, Klug CS, Gorski J. PLoS ONE 3 e3722 (2008)
  232. HLA class II amino acid epitopes as susceptibility markers of sarcoidosis. Voorter CE, Amicosante M, Berretta F, Groeneveld L, Drent M, van den Berg-Loonen EM. Tissue Antigens 70 18-27 (2007)
  233. Predicting peptide binding to MHC pockets via molecular modeling, implicit solvation, and global optimization. Schafroth HD, Floudas CA. Proteins 54 534-556 (2004)
  234. MHC allele-specific binding of a malaria peptide makes it become promiscuous on fitting a glycine residue into pocket 6. Vargas LE, Parra CA, Salazar LM, Guzmán F, Pinto M, Patarroyo ME. Biochem. Biophys. Res. Commun. 307 148-156 (2003)
  235. HLA-DP molecules bind cobalt: a possible explanation for the genetic association with hard metal disease. Potolicchio I, Festucci A, Hausler P, Sorrentino R. Eur. J. Immunol. 29 2140-2147 (1999)
  236. On the immunogenic properties of retro-inverso peptides. Total retro-inversion of T-cell epitopes causes a loss of binding to MHC II molecules. Hervé M, Maillere B, Mourier G, Texier C, Leroy S, Ménez A. Mol. Immunol. 34 157-163 (1997)
  237. Mapping T cell recognition: the identification of a T cell receptor residue critical to the specific interaction with an influenza hemagglutinin peptide. Wedderburn LR, Searle SJ, Rees AR, Lamb JR, Owen MJ. Eur. J. Immunol. 25 1654-1662 (1995)
  238. Positive association of DRB1 04 and DRB1 15 alleles with Fya immunization in a Southern European population. Picard C, Frassati C, Basire A, Buhler S, Galicher V, Ferrera V, Reviron D, Zappitelli JP, Bailly P, Chiaroni J. Transfusion 49 2412-2417 (2009)
  239. Augmentation of immune response by altered peptide ligands of the antigenic peptide in a human CD4+ T-cell clone reacting to TEL/AML1 fusion protein. Yun C, Senju S, Fujita H, Tsuji Y, Irie A, Matsushita S, Nishimura Y. Tissue Antigens 54 153-161 (1999)
  240. CD4+ and CD8+ T-cell clones from congenital rubella syndrome patients with IDDM recognize overlapping GAD65 protein epitopes. Implications for HLA class I and II allelic linkage to disease susceptibility. Ou D, Jonsen LA, Metzger DL, Tingle AJ. Hum. Immunol. 60 652-664 (1999)
  241. TAP, HLA-DQB1, and HLA-DRB1 polymorphism in Colombian patients with primary Sjögren's syndrome. Anaya JM, Correa PA, Mantilla RD, Arcos-Burgos M. Semin. Arthritis Rheum. 31 396-405 (2002)
  242. Influence of the NH2-terminal amino acid of the T cell receptor alpha chain on major histocompatibility complex (MHC) class II + peptide recognition. Seibel JL, Wilson N, Kozono H, Marrack P, Kappler JW. J. Exp. Med. 185 1919-1927 (1997)
  243. Polymorphic amino acid domains of the HLA-DQ molecule are associated with disease heterogeneity in myasthenia gravis. Hjelmström P, Giscombe R, Lefvert AK, Pirskanen R, Kockum I, Landin-Olsson M, Sanjeevi CB. J. Neuroimmunol. 65 125-131 (1996)
  244. Six new DR52-associated DRB1 alleles, three of DR8, two of DR11, and one of DR6, reflect a variety of mechanisms which generate polymorphism in the MHC. Smith AG, Nelson JL, Regen L, Guthrie LA, Donadi E, Mickelson EM, Hansen JA. Tissue Antigens 48 118-126 (1996)
  245. MHC allele frequency distributions under parasite-driven selection: A simulation model. Ejsmond MJ, Babik W, Radwan J. BMC Evol. Biol. 10 332 (2010)
  246. Recognition of coagulation factor VIII by CD4+ T cells of healthy humans. Hu GL, Okita DK, Diethelm-Okita BM, Conti-Fine BM. J. Thromb. Haemost. 1 2159-2166 (2003)
  247. Multiple sclerosis associated amino acids of polymorphic regions relevant for the HLA antigen binding are confined to HLA-DR2. Zipp F, Windemuth C, Pankow H, Dichgans J, Wienker T, Martin R, Müller C. Hum. Immunol. 61 1021-1030 (2000)
  248. Characterizing immunodominant and protective influenza hemagglutinin epitopes by functional activity and relative binding to major histocompatibility complex class II sites. Rajnavölgyi E, Horváth A, Gogolák P, Tóth GK, Fazekas G, Fridkin M, Pecht I. Eur. J. Immunol. 27 3105-3114 (1997)
  249. Characterization of structural features controlling the receptiveness of empty class II MHC molecules. Rupp B, Günther S, Makhmoor T, Schlundt A, Dickhaut K, Gupta S, Choudhary I, Wiesmüller KH, Jung G, Freund C, Falk K, Rötzschke O, Kühne R. PLoS ONE 6 e18662 (2011)
  250. Peptide-MHC class II complex stability governs CD4 T cell clonal selection. Baumgartner CK, Ferrante A, Nagaoka M, Gorski J, Malherbe LP. J. Immunol. 184 573-581 (2010)
  251. The rheumatoid arthritis-associated allele HLA-DR10 (DRB1*1001) shares part of its repertoire with HLA-DR1 (DRB1*0101) and HLA-DR4 (DRB*0401). Alvarez I, Collado J, Daura X, Colomé N, Rodríguez-García M, Gallart T, Canals F, Jaraquemada D. Arthritis Rheum. 58 1630-1639 (2008)
  252. HLA DR B1*04, *07-restricted epitopes on Keratin 17 for autoreactive T cells in psoriasis. Shen Z, Wang G, Fan JY, Li W, Liu YF. J. Dermatol. Sci. 38 25-39 (2005)
  253. A polymorphic pocket at the P10 position contributes to peptide binding specificity in class II MHC proteins. Zavala-Ruiz Z, Strug I, Anderson MW, Gorski J, Stern LJ. Chem. Biol. 11 1395-1402 (2004)
  254. Novel synthetic amino acid copolymers that inhibit autoantigen-specific T cell responses and suppress experimental autoimmune encephalomyelitis. Fridkis-Hareli M, Santambrogio L, Stern JN, Fugger L, Brosnan C, Strominger JL. J. Clin. Invest. 109 1635-1643 (2002)
  255. Conformational variants of class II MHC/peptide complexes induced by N- and C-terminal extensions of minimal peptide epitopes. Rötzschke O, Falk K, Mack J, Lau JM, Jung G, Strominger JL. Proc. Natl. Acad. Sci. U.S.A. 96 7445-7450 (1999)
  256. HLA-DRB1*0701 and DRB1*1401 are associated with genetic susceptibility to psoriasis vulgaris in a Taiwanese population. Jee SH, Tsai TF, Tsai WL, Liaw SH, Chang CH, Hu CY. Br. J. Dermatol. 139 978-983 (1998)
  257. Engineering protein for X-ray crystallography: the murine Major Histocompatibility Complex class II molecule I-Ad. Scott CA, Garcia KC, Stura EA, Peterson PA, Wilson IA, Teyton L. Protein Sci. 7 413-418 (1998)
  258. Biochemical characterization of the human diabetes-associated HLA-DQ8 allelic product: similarity to the major histocompatibility complex class II I-A(g)7 protein of non-obese diabetic mice. Reizis B, Altmann DM, Cohen IR. Eur. J. Immunol. 27 2478-2483 (1997)
  259. Negatively charged residues interacting with the p4 pocket confer binding specificity to DRB1*0401. Woulfe SL, Bono CP, Zacheis ML, Kirschmann DA, Baudino TA, Swearingen C, Karr RW, Schwartz BD. Arthritis Rheum. 38 1744-1753 (1995)
  260. Distinct subunit pairing criteria within the heterodimeric IL-12 cytokine family. Jones LL, Chaturvedi V, Uyttenhove C, Van Snick J, Vignali DA. Mol. Immunol. 51 234-244 (2012)
  261. Enthalpy-entropy compensation and cooperativity as thermodynamic epiphenomena of structural flexibility in ligand-receptor interactions. Ferrante A, Gorski J. J. Mol. Biol. 417 454-467 (2012)
  262. MHC class II DRB diversity in raccoons (Procyon lotor) reveals associations with raccoon rabies virus (Lyssavirus). Srithayakumar V, Castillo S, Rosatte RC, Kyle CJ. Immunogenetics 63 103-113 (2011)
  263. High-throughput engineering and analysis of peptide binding to class II MHC. Jiang W, Boder ET. Proc. Natl. Acad. Sci. U.S.A. 107 13258-13263 (2010)
  264. Evidence for role of transmembrane helix-helix interactions in the assembly of the Class II major histocompatibility complex. King G, Dixon AM. Mol Biosyst 6 1650-1661 (2010)
  265. Sequence analysis of the MHC class II DRB alleles in Alpine chamois (Rupicapra r. rupicapra). Schaschl H, Goodman SJ, Suchentrunk F. Dev. Comp. Immunol. 28 265-277 (2004)
  266. Optimization of peptide linker length in production of MHC class II/peptide tetrameric complexes increases yield and stability, and allows identification of antigen-specific CD4+T cells in peripheral blood mononuclear cells. Cunliffe SL, Wyer JR, Sutton JK, Lucas M, Harcourt G, Klenerman P, McMichael AJ, Kelleher AD. Eur. J. Immunol. 32 3366-3375 (2002)
  267. Stabilization of soluble, low-affinity HLA-DM/HLA-DR1 complexes by leucine zippers. Busch R, Pashine A, Garcia KC, Mellins ED. J. Immunol. Methods 263 111-121 (2002)
  268. Substitution of aspartic acid at beta57 with alanine alters MHC class II peptide binding activity but not protein stability: HLA-DQ (alpha1*0201, beta1*0302) and (alpha1*0201, beta1*0303). Sato AK, Sturniolo T, Sinigaglia F, Stern LJ. Hum. Immunol. 60 1227-1236 (1999)
  269. Synthetic peptides that inhibit binding of the collagen type II 261-273 epitope to rheumatoid arthritis-associated HLA-DR1 and -DR4 molecules and collagen-specific T-cell responses. Fridkis-Hareli M, Rosloniec EF, Fugger L, Strominger JL. Hum. Immunol. 61 640-650 (2000)
  270. Binding specificity of a class II-restricted hepatitis B epitope by DR molecules from responder and nonresponder vaccine recipients. Schuenke KW, Cook RG, Rich RR. Hum. Immunol. 59 783-793 (1998)
  271. T cell responses to 53-kDa outer membrane protein of Porphyromonas gingivalis in humans with early-onset periodontitis. Ohyama H, Matsushita S, Kato N, Nishimura F, Oyaizu K, Kokeguchi S, Kurihara H, Takashiba S, Nishimura Y, Murayama Y. Hum. Immunol. 59 635-643 (1998)
  272. Analysis of HLA-DPB1 polymorphisms in African-Americans with sarcoidosis. Maliarik MJ, Chen KM, Major ML, Sheffer RG, Popovich J, Rybicki BA, Iannuzzi MC. Am. J. Respir. Crit. Care Med. 158 111-114 (1998)
  273. Binding of gluten-derived peptides to the HLA-DQ2 (alpha1*0501, beta1*0201) molecule, assessed in a cellular assay. Shidrawi RG, Parnell ND, Ciclitira PJ, Travers P, Evan G, Rosen-Bronson S. Clin. Exp. Immunol. 111 158-165 (1998)
  274. Modulation of promiscuous T cell receptor recognition by mutagenesis of CDR2 residues. Brawley JV, Concannon P. J. Exp. Med. 183 2043-2051 (1996)
  275. An insulin peptide that binds an alternative site in class II major histocompatibility complex. Tompkins SM, Moore JC, Jensen PE. J. Exp. Med. 183 857-866 (1996)
  276. Peptide binding prediction for the human class II MHC allele HLA-DP2: a molecular docking approach. Patronov A, Dimitrov I, Flower DR, Doytchinova I. BMC Struct. Biol. 11 32 (2011)
  277. The structure of superantigen complexed with TCR and MHC reveals novel insights into superantigenic T cell activation. Saline M, Rödström KE, Fischer G, Orekhov VY, Karlsson BG, Lindkvist-Petersson K. Nat Commun 1 119 (2010)
  278. Structural basis for the presentation of tumor-associated MHC class II-restricted phosphopeptides to CD4+ T cells. Li Y, Depontieu FR, Sidney J, Salay TM, Engelhard VH, Hunt DF, Sette A, Topalian SL, Mariuzza RA. J. Mol. Biol. 399 596-603 (2010)
  279. Second-generation peptidomimetic inhibitors of antigen presentation effectively treat autoimmune diseases in HLA-DR-transgenic mouse models. Rosloniec EF, Brandstetter T, Leyer S, Schwaiger FW, Nagy ZA. J. Autoimmun. 27 182-195 (2006)
  280. Crystal structure of Mycoplasma arthritidis mitogen complexed with HLA-DR1 reveals a novel superantigen fold and a dimerized superantigen-MHC complex. Zhao Y, Li Z, Drozd SJ, Guo Y, Mourad W, Li H. Structure 12 277-288 (2004)
  281. Mutational analysis of critical residues determining antigen presentation and activation of HLA-DQ0602 restricted T-cell clones. Reichstetter S, Papadopoulos GK, Moustakas AK, Swanson E, Liu AW, Beheray S, Ettinger RA, Nepom GT, Kwok WW. Hum. Immunol. 63 185-193 (2002)
  282. Differences between T-cell reactivities to major myelin protein-derived peptides in opticospinal and conventional forms of multiple sclerosis and healthy controls. Minohara M, Ochi H, Matsushita S, Irie A, Nishimura Y, Kira J. Tissue Antigens 57 447-456 (2001)
  283. Critical Lym-1 binding residues on polymorphic HLA-DR molecules. Rose LM, Deng CT, Scott SL, Xiong CY, Lamborn KR, Gumerlock PH, DeNardo GL, Meares CF. Mol. Immunol. 36 789-797 (1999)
  284. Evaluating candidate autoantigens in rheumatoid arthritis. Cope AP, Sønderstrup G. Springer Semin. Immunopathol. 20 23-39 (1998)
  285. HLA-DPbeta residue 69 plays a crucial role in allorecognition. Díaz G, Catálfamo M, Coiras MT, Alvarez AM, Jaraquemada D, Nombela C, Sánchez-Pérez M, Arroyo J. Tissue Antigens 52 27-36 (1998)
  286. Analysis of critical residues of HLA-DQ6 molecules in insulin-dependent diabetes mellitus. Sanjeevi CB, DeWeese C, Landin-Olsson M, Kockum I, Dahlquist G, Lernmark A, Lybrand TP. Tissue Antigens 50 61-65 (1997)
  287. Specific T cell recognition of kinetic isomers in the binding of peptide to class II major histocompatibility complex. Rabinowitz JD, Tate K, Lee C, Beeson C, McConnell HM. Proc. Natl. Acad. Sci. U.S.A. 94 8702-8707 (1997)
  288. A retro-inverso analog mimics the cognate peptide epitope of a CD4+ T cell clone. Bartnes K, Hannestad K, Guichard G, Briand JP. Eur. J. Immunol. 27 1387-1391 (1997)
  289. The functional half-life of H-2Kd-restricted T cell epitopes on living cells. Eberl G, Widmann C, Corradin G. Eur. J. Immunol. 26 1993-1999 (1996)
  290. Peptide motifs of HLA-DR4/DR53 (DRB1*0405/DRB4*0101) molecules. Kinouchi R, Kobayasi H, Sato K, Kimura S, Katagiri M. Immunogenetics 40 376-378 (1994)
  291. Elongated peptides, not the predicted nonapeptide stimulate a major histocompatibility complex class I-restricted cytotoxic T lymphocyte clone with specificity for a bacterial heat shock protein. Schoel B, Zügel U, Ruppert T, Kaufmann SH. Eur. J. Immunol. 24 3161-3169 (1994)
  292. Comparison of the effects of amino acid substitutions and beta-N- vs. alpha-O-glycosylation on the T-cell stimulatory activity and conformation of an epitope on the rabies virus glycoprotein. Otvos L, Krivulka GR, Urge L, Szendrei GI, Nagy L, Xiang ZQ, Ertl HC. Biochim. Biophys. Acta 1267 55-64 (1995)
  293. Cross-recognition by T cells of an epitope shared by two unrelated mycobacterial antigens. Harris DP, Vordermeier HM, Singh M, Moreno C, Jurcevic S, Ivanyi J. Eur. J. Immunol. 25 3173-3179 (1995)
  294. Antibody stabilization of peptide-MHC multimers reveals functional T cells bearing extremely low-affinity TCRs. Tungatt K, Bianchi V, Crowther MD, Powell WE, Schauenburg AJ, Trimby A, Donia M, Miles JJ, Holland CJ, Cole DK, Godkin AJ, Peakman M, Straten PT, Svane IM, Sewell AK, Dolton G. J. Immunol. 194 463-474 (2015)
  295. Comprehensive analysis of MHC class II genes in teleost fish genomes reveals dispensability of the peptide-loading DM system in a large part of vertebrates. Dijkstra JM, Grimholt U, Leong J, Koop BF, Hashimoto K. BMC Evol. Biol. 13 260 (2013)
  296. Mapping the HLA-DO/HLA-DM complex by FRET and mutagenesis. Yoon T, Macmillan H, Mortimer SE, Jiang W, Rinderknecht CH, Stern LJ, Mellins ED. Proc. Natl. Acad. Sci. U.S.A. 109 11276-11281 (2012)
  297. MHC evolution in three salmonid species: a comparison between class II alpha and beta genes. Gómez D, Conejeros P, Marshall SH, Consuegra S. Immunogenetics 62 531-542 (2010)
  298. HLA-DM mediates peptide exchange by interacting transiently and repeatedly with HLA-DR1. Narayan K, Su KW, Chou CL, Khoruzhenko S, Sadegh-Nasseri S. Mol. Immunol. 46 3157-3162 (2009)
  299. Peptide length significantly influences in vitro affinity for MHC class II molecules. O'Brien C, Flower DR, Feighery C. Immunome Res 4 6 (2008)
  300. Altered keratin 17 peptide ligands inhibit in vitro proliferation of keratinocytes and T cells isolated from patients with psoriasis. Shen Z, Chen L, Liu YF, Gao TW, Wang G, Fan XL, Fan JY, Fan PS, Li CY, Liu B, Dang YP, Li CX. J. Am. Acad. Dermatol. 54 992-1002 (2006)
  301. Association between the HLA-DRB1 gene and clinical features of systemic sclerosis in Korea. Joung CI, Jun JB, Chung WT, Song GG, Choe JY, Chang HK, Yoo DH. Scand. J. Rheumatol. 35 39-43 (2006)
  302. Frequency of DRB1-DQB1 two-locus haplotypes in tuberculosis: preliminary report. Dubaniewicz A, Moszkowska G, Szczerkowska Z. Tuberculosis (Edinb) 85 259-267 (2005)
  303. Allele effects in MHC-peptide interactions: a theoretical analysis of HLA-DRbeta1*0101-HA and HLA-DRbeta1*0401-HA complexes. Cárdenas C, Ortiz M, Balbín A, Villaveces JL, Patarroyo ME. Biochem. Biophys. Res. Commun. 330 1162-1167 (2005)
  304. Molecular characterization of the OspA(161-175) T cell epitope associated with treatment-resistant Lyme arthritis: differences among the three pathogenic species of Borrelia burgdorferi sensu lato. Drouin EE, Glickstein LJ, Steere AC. J. Autoimmun. 23 281-292 (2004)
  305. Amino acid residue at position 13 in HLA-DR beta chain plays a critical role in the development of Kaposi's sarcoma in AIDS patients. Gayà A, Esteve A, Casabona J, McCarthy JJ, Martorell J, Schulz TF, Whitby D, EURO-SHAKS working group. AIDS 18 199-204 (2004)
  306. Naturally processed measles virus peptide eluted from class II HLA-DRB1*03 recognized by T lymphocytes from human blood. Ovsyannikova IG, Johnson KL, Naylor S, Muddiman DC, Poland GA. Virology 312 495-506 (2003)
  307. Synthetic peptides that inhibit binding of the myelin basic protein 85-99 epitope to multiple sclerosis-associated HLA-DR2 molecules and MBP-specific T-cell responses. Fridkis-Hareli M, Stern JN, Fugger L, Strominger JL. Hum. Immunol. 62 753-763 (2001)
  308. Helper T-cell epitope immunodominance associated with structurally stable segments of hen egg lysozyme and HIV gp120. Landry SJ. J. Theor. Biol. 203 189-201 (2000)
  309. Ligand motif of the autoimmune disease-associated mouse MHC class II molecule H2-A(s). Kalbus M, Fleckenstein BT, Offenhäusser M, Blüggel M, Melms A, Meyer HE, Rammensee HG, Martin R, Jung G, Sommer N. Eur. J. Immunol. 31 551-562 (2001)
  310. N-terminal elongation of a peptide determinant beyond the first primary anchor improves binding to H-2 I-Ad and HLA-DR1 by backbone-dependent and aromatic side chain-dependent interactions, respectively. Bartnes K, Leon F, Briand JP, Travers PJ, Hannestad K. Eur. J. Immunol. 29 189-195 (1999)
  311. Alteration of a single hydrogen bond between class II molecules and peptide results in rapid degradation of class II molecules after invariant chain removal. Ceman S, Wu S, Jardetzky TS, Sant AJ. J. Exp. Med. 188 2139-2149 (1998)
  312. Identification of a peptide inducing experimental autoimmune uveoretinitis (EAU) in H-2Ak-carrying mice. Namba K, Ogasawara K, Kitaichi N, Matsuki N, Takahashi A, Sasamoto Y, Kotake S, Matsuda H, Iwabuchi K, Ohno S, Onoé K. Clin. Exp. Immunol. 111 442-449 (1998)
  313. Pathway of detergent-mediated and peptide ligand-mediated refolding of heterodimeric class II major histocompatibility complex (MHC) molecules. Stöckel J, Döring K, Malotka J, Jähnig F, Dornmair K. Eur. J. Biochem. 248 684-691 (1997)
  314. Late events in the intracellular sorting of major histocompatibility complex class II molecules are regulated by the 80-82 segment of the class II beta chain. Tan LJ, Ceman S, Chervonsky A, Rodriguez-Paris J, Steck TL, Sant AJ. Eur. J. Immunol. 27 1479-1488 (1997)
  315. Preferential presentation of herpes simplex virus T-cell antigen by HLA DQA1*0501/DQB1*0201 in comparison to HLA DQA1*0201/DQB1*0201. Koelle DM, Johnson ML, Ekstrom AN, Byers P, Kwok WW. Hum. Immunol. 53 195-205 (1997)
  316. Identification of HLA-DR9 (DRB1*0901)-binding peptide motifs using a phage fUSE5 random peptide library. Fujisao S, Matsushita S, Nishi T, Nishimura Y. Hum. Immunol. 45 131-136 (1996)
  317. HLA-DRα1 constructs block CD74 expression and MIF effects in experimental autoimmune encephalomyelitis. Meza-Romero R, Benedek G, Yu X, Mooney JL, Dahan R, Duvshani N, Bucala R, Offner H, Reiter Y, Burrows GG, Vandenbark AA. J. Immunol. 192 4164-4173 (2014)
  318. Minimal conformational plasticity enables TCR cross-reactivity to different MHC class II heterodimers. Holland CJ, Rizkallah PJ, Vollers S, Calvo-Calle JM, Madura F, Fuller A, Sewell AK, Stern LJ, Godkin A, Cole DK. Sci Rep 2 629 (2012)
  319. HLA-DRB1-DQB1 haplotypes confer susceptibility and resistance to multiple sclerosis in Sardinia. Cocco E, Sardu C, Pieroni E, Valentini M, Murru R, Costa G, Tranquilli S, Frau J, Coghe G, Carboni N, Floris M, Contu P, Marrosu MG. PLoS ONE 7 e33972 (2012)
  320. Tandem duplication, circular permutation, molecular adaptation: how Solanaceae resist pests via inhibitors. Kong L, Ranganathan S. BMC Bioinformatics 9 Suppl 1 S22 (2008)
  321. Predicting peptides bound to I-Ag7 class II histocompatibility molecules using a novel expectation-maximization alignment algorithm. Chang KY, Suri A, Unanue ER. Proteomics 7 367-377 (2007)
  322. Analog peptides of type II collagen can suppress arthritis in HLA-DR4 (DRB1*0401) transgenic mice. Sakurai Y, Brand DD, Tang B, Rosloniec EF, Stuart JM, Kang AH, Myers LK. Arthritis Res. Ther. 8 R150 (2006)
  323. Identification of human T cell epitopes in Japanese cypress pollen allergen, Cha o 1, elucidates the intrinsic mechanism of cross-allergenicity between Cha o 1 and Cry j 1, the major allergen of Japanese cedar pollen, at the T cell level. Sone T, Dairiki K, Morikubo K, Shimizu K, Tsunoo H, Mori T, Kino K. Clin. Exp. Allergy 35 664-671 (2005)
  324. Mapping of a protective helper T cell epitope of human influenza A virus hemagglutinin. Gogolák P, Simon A, Horváth A, Réthi B, Simon I, Berkics K, Rajnavölgyi E, Tóth GK. Biochem. Biophys. Res. Commun. 270 190-198 (2000)
  325. HLA class I and II alleles and susceptibility to generalized pustular psoriasis: significant associations with HLA-Cw1 and HLA-DQB1*0303. Ozawa A, Miyahara M, Sugai J, Iizuka M, Kawakubo Y, Matsuo I, Ohkido M, Naruse T, Ando H, Inoko H, Kobayashi H, Ohkawara A, Takahashi H, Iizuka H, Morita E, Yamamoto S, Hide M, Taniguchi Y, Shimizu M. J. Dermatol. 25 573-581 (1998)
  326. Binding affinity independent contribution of peptide length to the stability of peptide-HLA-DR complexes in live antigen presenting cells. Siklodi B, Vogt AB, Kropshofer H, Falcioni F, Molina M, Bolin DR, Campbell R, Hämmerling GJ, Nagy ZA. Hum. Immunol. 59 463-471 (1998)
  327. Identification of mimicry peptides based on sequential motifs of epitopes derived from 65-kDa glutamic acid decarboxylase. Bach JM, Otto H, Jung G, Cohen H, Boitard C, Bach JF, van Endert PM. Eur. J. Immunol. 28 1902-1910 (1998)
  328. Structural differences between HLA-DQ molecules associated with myasthenia gravis characterized by molecular modeling. Hjelmström P, DeWeese-Scott C, Penzotti JE, Lybrand TP, Sanjeevi CB. J. Neuroimmunol. 85 102-105 (1998)
  329. Promiscuous T-cell recognition of a rubella capsid protein epitope restricted by DRB1*0403 and DRB1*0901 molecules sharing an HLA DR supertype. Ou D, Mitchell LA, Décarie D, Tingle AJ, Nepom GT. Hum. Immunol. 59 149-157 (1998)
  330. A sensitive fluorometric assay for quantitatively measuring specific peptide binding to HLA class I and class II molecules. Ottenhoff TH, Geluk A, Toebes M, Benckhuijsen WE, van Meijgaarden KE, Drijfhout JW. J. Immunol. Methods 200 89-97 (1997)
  331. A T cell receptor V alpha domain expressed in bacteria: does it dimerize in solution? Plaksin D, Chacko S, McPhie P, Bax A, Padlan EA, Margulies DH. J. Exp. Med. 184 1251-1258 (1996)
  332. Immunogenicity of peptides coupled with multiple T-cell epitopes of a surface protein antigen of Streptococcus mutans. Senpuku H, Iizima T, Yamaguchi Y, Nagata S, Ueno Y, Saito M, Hanada N, Nisizawa T. Immunology 88 275-283 (1996)
  333. News Backwards and forwards binding. Saraste M, Musacchio A. Nat. Struct. Biol. 1 835-837 (1994)
  334. Human leukocyte antigen class II haplotypes affect clinical characteristics and progression of type 1 autoimmune hepatitis in Japan. Umemura T, Katsuyama Y, Yoshizawa K, Kimura T, Joshita S, Komatsu M, Matsumoto A, Tanaka E, Ota M. PLoS ONE 9 e100565 (2014)
  335. Re-Directing CD4(+) T Cell Responses with the Flanking Residues of MHC Class II-Bound Peptides: The Core is Not Enough. Holland CJ, Cole DK, Godkin A. Front Immunol 4 172 (2013)
  336. Comparison of 454 pyrosequencing methods for characterizing the major histocompatibility complex of nonmodel species and the advantages of ultra deep coverage. Oomen RA, Gillett RM, Kyle CJ. Mol Ecol Resour 13 103-116 (2013)
  337. Towards universal structure-based prediction of class II MHC epitopes for diverse allotypes. Bordner AJ. PLoS ONE 5 e14383 (2010)
  338. Anti-group A streptococcal vaccine epitope: structure, stability, and its ability to interact with HLA class II molecules. Guilherme L, Alba MP, Ferreira FM, Oshiro SE, Higa F, Patarroyo ME, Kalil J. J. Biol. Chem. 286 6989-6998 (2011)
  339. Molecular and structural determinants of adamantyl susceptibility to HLA-DRs allelic variants: an in silico approach to understand the mechanism of MLEs. Zaheer-ul-Haq, Khan W. J. Comput. Aided Mol. Des. 25 81-101 (2011)
  340. pDOCK: a new technique for rapid and accurate docking of peptide ligands to Major Histocompatibility Complexes. Khan JM, Ranganathan S. Immunome Res 6 Suppl 1 S2 (2010)
  341. Characterization of major histocompatibility complex (MHC) DRB exon 2 and DRA exon 3 fragments in a primary terrestrial rabies vector (Procyon lotor). Castillo S, Srithayakumar V, Meunier V, Kyle CJ. PLoS ONE 5 e12066 (2010)
  342. 3D analysis of the TCR/pMHCII complex formation in monkeys vaccinated with the first peptide inducing sterilizing immunity against human malaria. Patarroyo MA, Bermúdez A, López C, Yepes G, Patarroyo ME. PLoS ONE 5 e9771 (2010)
  343. The binding of antigenic peptides to HLA-DR is influenced by interactions between pocket 6 and pocket 9. James EA, Moustakas AK, Bui J, Nouv R, Papadopoulos GK, Kwok WW. J. Immunol. 183 3249-3258 (2009)
  344. Immunogenetics of mycobacterial infections in the North Indian population. Singh M, Balamurugan A, Katoch K, Sharma SK, Mehra NK. Tissue Antigens 69 Suppl 1 228-230 (2007)
  345. Open reading frame sequencing and structure-based alignment of polypeptides encoded by RT1-Bb, RT1-Ba, RT1-Db, and RT1-Da alleles. Ettinger RA, Moustakas AK, Lobaton SD. Immunogenetics 56 585-596 (2004)
  346. MHC-linked susceptibility to type 1 diabetes: a structural perspective. Wucherpfennig KW. Ann. N. Y. Acad. Sci. 1005 119-127 (2003)
  347. Analysis of DQB1 allele frequencies in pulmonary tuberculosis: preliminary report. Dubaniewicz A, Moszkowska G, Szczerkowska Z, Hoppe A. Thorax 58 890-891 (2003)
  348. Association of HLA and T-cell receptor gene polymorphisms with Semple rabies vaccine-induced autoimmune encephalomyelitis. Piyasirisilp S, Schmeckpeper BJ, Chandanayingyong D, Hemachudha T, Griffin DE. Ann. Neurol. 45 595-600 (1999)
  349. Comparison of 454 pyrosequencing methods for characterizing the major histocompatibility complex of nonmodel species and the advantages of ultra deep coverage Oomen RA, Gillett RM, Kyle CJ. Mol Ecol Resour 13 103-116 (2013)
  350. Identification of Streptococcus mutans PAc peptide motif binding with human MHC class II molecules (DRB1*0802, *1101, *1401 and *1405). Senpuku H, Yanagi K, Nisizawa T. Immunology 95 322-330 (1998)
  351. Interaction of pigeon cytochrome c-(43-58) peptide analogs with either T cell antigen receptor or I-Ab molecule. Itoh Y, Kajino K, Ogasawara K, Takahashi A, Namba K, Negishi I, Matsuki N, Iwabuchi K, Kakinuma M, Good RA, Onoé K. Proc. Natl. Acad. Sci. U.S.A. 94 12047-12052 (1997)
  352. Analysis of anchor residues in a naturally processed HLA-DR53 ligand. Kobayashi H, Kokubo T, Abe Y, Sato K, Kimura S, Miyokawa N, Katagiri M. Immunogenetics 44 366-371 (1996)
  353. Unique role of thyroxine in T cell recognition of a pathogenic peptide in experimental autoimmune thyroiditis. Dawe KI, Hutchings PR, Geysen M, Champion BR, Cooke A, Roitt IM. Eur. J. Immunol. 26 768-772 (1996)
  354. Susceptibility to HLA-DM protein is determined by a dynamic conformation of major histocompatibility complex class II molecule bound with peptide. Yin L, Trenh P, Guce A, Wieczorek M, Lange S, Sticht J, Jiang W, Bylsma M, Mellins ED, Freund C, Stern LJ. J. Biol. Chem. 289 23449-23464 (2014)
  355. Molecular basis of a dominant T cell response to an HIV reverse transcriptase 8-mer epitope presented by the protective allele HLA-B*51:01. Motozono C, Kuse N, Sun X, Rizkallah PJ, Fuller A, Oka S, Cole DK, Sewell AK, Takiguchi M. J. Immunol. 192 3428-3434 (2014)
  356. Molecular dynamics simulations to provide insights into epitopes coupled to the soluble and membrane-bound MHC-II complexes. Bello M, Correa-Basurto J. PLoS ONE 8 e72575 (2013)
  357. Transport of misfolded endoplasmic reticulum proteins to the cell surface by MHC class II molecules. Jiang Y, Arase N, Kohyama M, Hirayasu K, Suenaga T, Jin H, Matsumoto M, Shida K, Lanier LL, Saito T, Arase H. Int. Immunol. 25 235-246 (2013)
  358. A Peptide/MHCII conformer generated in the presence of exchange peptide is substrate for HLA-DM editing. Ferrante A, Gorski J. Sci Rep 2 386 (2012)
  359. Pathway-based analysis of genetic susceptibility to cervical cancer in situ: HLA-DPB1 affects risk in Swedish women. Ivansson EL, Juko-Pecirep I, Erlich HA, Gyllensten UB. Genes Immun. 12 605-614 (2011)
  360. Genetic structure and contrasting selection pattern at two major histocompatibility complex genes in wild house mouse populations. Cížková D, Gouy de Bellocq J, Baird SJ, Piálek J, Bryja J. Heredity (Edinb) 106 727-740 (2011)
  361. Lineage pattern, trans-species polymorphism, and selection pressure among the major lineages of feline MHC-DRB peptide-binding region. Wei K, Zhang Z, Wang X, Zhang W, Xu X, Shen F, Yue B. Immunogenetics 62 307-317 (2010)
  362. Balancing and directional selection at exon-2 of the MHC DQB1 locus among populations of odontocete cetaceans. Vassilakos D, Natoli A, Dahlheim M, Hoelzel AR. Mol. Biol. Evol. 26 681-689 (2009)
  363. Genetic drift vs. natural selection in a long-term small isolated population: major histocompatibility complex class II variation in the Gulf of California endemic porpoise (Phocoena sinus). Munguia-Vega A, Esquer-Garrigos Y, Rojas-Bracho L, Vazquez-Juarez R, Castro-Prieto A, Flores-Ramirez S. Mol. Ecol. 16 4051-4065 (2007)
  364. Sequence variability at three MHC loci of finless porpoises (Neophocaena phocaenoides). Xu S, Sun P, Zhou K, Yang G. Immunogenetics 59 581-592 (2007)
  365. A consensus strategy for combining HLA-DR binding algorithms. Mallios RR. Hum. Immunol. 64 852-856 (2003)
  366. The role of the map protein in Staphylococcus aureus matrix protein and eukaryotic cell adherence. Kreikemeyer B, McDevitt D, Podbielski A. Int. J. Med. Microbiol. 292 283-295 (2002)
  367. A single amino acid deletion in the antigen binding site of BoLA-DRB3 is predicted to affect peptide binding. Sitte K, Brinkworth R, East IJ, Jazwinska EC. Vet. Immunol. Immunopathol. 85 129-135 (2002)
  368. HLA class II alleles in Japanese patients with immune thrombocytopenic purpura. Associations with anti-platelet glycoprotein autoantibodies and responses to splenectomy. Kuwana M, Kaburaki J, Pandey JP, Murata M, Kawakami Y, Inoko H, Ikeda Y. Tissue Antigens 56 337-343 (2000)
  369. Peptide analogues as a strategy to induce tolerance in T cells with indirect allospecificity. Frasca L, Tamir A, Jurcevic S, Marinari B, Monizio A, Sorrentino R, Carbonari M, Piccolella E, Lechler RI, Lombardi G. Transplantation 70 631-640 (2000)
  370. Magnitude of structural changes of the T-cell receptor binding regions determine the strength of T-cell antagonism: molecular dynamics simulations of HLA-DR4 (DRB1*0405) complexed with analogue peptide. Toh H, Kamikawaji N, Tana T, Muta S, Sasazuki T, Kuhara S. Protein Eng. 13 423-429 (2000)
  371. A new predictive model for insulin-dependent diabetes mellitus susceptibility based on combinations of molecular HLA-DRB1 and HLA-DQB1 pockets. Djoulah S, Busson M, Sasazuki T, Maillere B, Yasunaga S, Kimura A, Charron D, Hors J. Tissue Antigens 54 341-348 (1999)
  372. Immunosuppressory mini-regions of HLA-DP and HLA-DR. Szewczuk Z, Wilczyński A, Stefanowicz P, Fedorowicz W, Siemion IZ, Wieczorek Z. Mol. Immunol. 36 525-533 (1999)
  373. Overexpression of human homologs of the bacterial DnaJ chaperone in the synovial tissue of patients with rheumatoid arthritis. Kurzik-Dumke U, Schick C, Rzepka R, Melchers I. Arthritis Rheum. 42 210-220 (1999)
  374. Naturally processed peptides from HLA-DQ7 (alpha1*0501-beta1*0301): influence of both alpha and beta chain polymorphism in the HLA-DQ peptide binding specificity. Khalil-Daher I, Boisgérault F, Feugeas JP, Tieng V, Toubert A, Charron D. Eur. J. Immunol. 28 3840-3849 (1998)
  375. MHC-DRB allelic sequences incorporate distinct intragenic trans-specific segments. Gaur LK, Nepom GT, Snyder KE, Anderson J, Pandarpurkar M, Yadock W, Heise ER. Tissue Antigens 49 342-355 (1997)
  376. Covalent HLA-B27/peptide complex induced by specific recognition of an aziridine mimic of arginine. Weiss GA, Valentekovich RJ, Collins EJ, Garboczi DN, Lane WS, Schreiber SL, Wiley DC. Proc. Natl. Acad. Sci. U.S.A. 93 10945-10948 (1996)
  377. H2-M polymorphism in mice susceptible to collagen-induced arthritis involves the peptide binding groove. Walter W, Loos M, Maeurer MJ. Immunogenetics 44 19-26 (1996)
  378. Polymorphic structural features of modelled HLA-DQ molecules segregate according to susceptibility or resistance to IDDM. Routsias J, Papadopoulos GK. Diabetologia 38 1251-1261 (1995)
  379. T cell receptor and peptide-contacting residues in the HLA-DR17(3) beta 1 chain. Geluk A, Fu XT, van Meijgaarden KE, Jansen YY, De Vries RR, Karr RW, Ottenhoff TH. Eur. J. Immunol. 24 3241-3244 (1994)
  380. HLA-DR residues accessible under the peptide-binding groove contribute to polymorphic antibody epitopes. Fu XT, Drover S, Marshall WH, Karr RW. Hum. Immunol. 43 243-250 (1995)
  381. Structural and dynamical insights on HLA-DR2 complexes that confer susceptibility to multiple sclerosis in Sardinia: a molecular dynamics simulation study. Kumar A, Cocco E, Atzori L, Marrosu MG, Pieroni E. PLoS ONE 8 e59711 (2013)
  382. Modification of the carboxy-terminal flanking region of a universal influenza epitope alters CD4⁺ T-cell repertoire selection. Cole DK, Gallagher K, Lemercier B, Holland CJ, Junaid S, Hindley JP, Wynn KK, Gostick E, Sewell AK, Gallimore AM, Ladell K, Price DA, Gougeon ML, Godkin A. Nat Commun 3 665 (2012)
  383. Association of HLA class II alleles with sensitization to cow dander Bos d 2, an important occupational allergen. Kauppinen A, Peräsaari J, Taivainen A, Kinnunen T, Saarelainen S, Rytkönen-Nissinen M, Jeal H, Jones M, Virtanen T. Immunobiology 217 8-12 (2012)
  384. Dana-Farber repository for machine learning in immunology. Zhang GL, Lin HH, Keskin DB, Reinherz EL, Brusic V. J. Immunol. Methods 374 18-25 (2011)
  385. Polymorphism and gene organization of water buffalo MHC-DQB genes show homology to the BoLA DQB region. Sena L, Schneider MP, Brenig BB, Honeycutt RL, Honeycutt DA, Womack JE, Skow LC. Anim. Genet. 42 378-385 (2011)
  386. Analysis of the binding of gluten T-cell epitopes to various human leukocyte antigen class II molecules. Bergseng E, Sidney J, Sette A, Sollid LM. Hum. Immunol. 69 94-100 (2008)
  387. The presence of glutamic acid at positions 71 or 74 in pocket 4 of the HLA-DRbeta1 chain is associated with the clinical course of multiple sclerosis. Greer JM, Pender MP. J. Neurol. Neurosurg. Psychiatr. 76 656-662 (2005)
  388. Quantum chemical analysis explains hemagglutinin peptide-MHC Class II molecule HLA-DRbeta1*0101 interactions. Cárdenas C, Villaveces JL, Bohórquez H, Llanos E, Suárez C, Obregón M, Patarroyo ME. Biochem. Biophys. Res. Commun. 323 1265-1277 (2004)
  389. Inhibition of T-cell activation with HLA-DR1/DR4 restricted Non-T-cell stimulating peptides. Zhou Q, Cheng Y, Lü H, Zhou W, Li Z. Hum. Immunol. 64 857-865 (2003)
  390. Dynamic flexibility of a peptide-binding groove of human HLA-DR1 class II MHC molecules: normal mode analysis of the antigen peptide-class II MHC complex. Nojima H, Takeda-Shitaka M, Kurihara Y, Kamiya K, Umeyama H. Chem. Pharm. Bull. 51 923-928 (2003)
  391. Isolation and rapid identification of an abundant self-peptide from class II HLA-DRB1*0401 alleles induced by measles vaccine virus infection. Ovsyannikova IG, Johnson KL, Naylor S, Poland GA. J. Immunol. Methods 246 1-12 (2000)
  392. Function-related regulation of the stability of MHC proteins. Simon A, Dosztányi Z, Rajnavölgyi E, Simon I. Biophys. J. 79 2305-2313 (2000)
  393. Class II antigen processing defects in two H2d mouse cell lines are caused by point mutations in the H2-DMa gene. Russell HI, York IA, Rock KL, Monaco JJ. Eur. J. Immunol. 29 905-911 (1999)
  394. An endogenously processed self peptide and the corresponding exogenous peptide bound to the same MHC class II molecule could be distinct ligands for TCR with different kinetic stability. Gyotoku T, Fukui Y, Sasazuki T. Eur. J. Immunol. 28 4050-4061 (1998)
  395. Processing of the DRB1*1103-restricted measles virus nucleoprotein determinant 185-199 in the endosomal compartment. Demotz S, Ammerlaan W, Fournier P, Muller CP, Barbey C. Clin. Exp. Immunol. 114 228-235 (1998)
  396. RGD sequences in several receptor proteins: novel cell adhesion function of receptors? Papadopoulos GK, Ouzounis C, Eliopoulos E. Int. J. Biol. Macromol. 22 51-57 (1998)
  397. A predictive method for the evaluation of peptide binding in pocket 1 of HLA-DRB1 via global minimization of energy interactions. Androulakis IP, Nayak NN, Ierapetritou MG, Monos DS, Floudas CA. Proteins 29 87-102 (1997)
  398. A novel, highly efficient peptide-HLA class I binding assay using unfolded heavy chain molecules: identification of HIV-1 derived peptides that bind to HLA-A*0201 and HLA-A*0301. Tan TL, Geluk A, Toebes M, Ottenhoff TH, Drijfhout JW. J. Immunol. Methods 205 201-209 (1997)
  399. Augmentation of immune response by an analog of the antigenic peptide in a human T-cell clone recognizing mutated Ras-derived peptides. Yokomizo H, Matsushita S, Fujisao S, Murakami S, Fujita H, Shirouzu M, Yokoyama S, Ogawa M, Nishimura Y. Hum. Immunol. 52 22-32 (1997)
  400. Binding motifs predict major histocompatibility complex class II-restricted epitopes in the Sendai virus M protein. Cole GA, Tao T, Hogg TL, Ryan KW, Woodland DL. J. Virol. 69 8057-8060 (1995)
  401. An immunogenic personal neoantigen vaccine for patients with melanoma. Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, Chen C, Olive O, Carter TA, Li S, Lieb DJ, Eisenhaure T, Gjini E, Stevens J, Lane WJ, Javeri I, Nellaiappan K, Salazar AM, Daley H, Seaman M, Buchbinder EI, Yoon CH, Harden M, Lennon N, Gabriel S, Rodig SJ, Barouch DH, Aster JC, Getz G, Wucherpfennig K, Neuberg D, Ritz J, Lander ES, Fritsch EF, Hacohen N, Wu CJ. Nature 547 217-221 (2017)
  402. Evidence for evolutionary convergence at MHC in two broadly distributed mesocarnivores. Srithayakumar V, Castillo S, Mainguy J, Kyle CJ. Immunogenetics 64 289-301 (2012)
  403. MHC class II DRB diversity, selection pattern and population structure in a neotropical bat species, Noctilio albiventris. Schad J, Dechmann DK, Voigt CC, Sommer S. Heredity (Edinb) 107 115-126 (2011)
  404. Anti-"Mi(a)" immunization is associated with HLA-DRB1*0901. Chu CC, Ho HT, Lee HL, Chan YS, Chang FJ, Wang CL, Lin M. Transfusion 49 472-478 (2009)
  405. Are bacterial vaccine antigens T-cell epitope depleted? Halling-Brown M, Sansom CE, Davies M, Titball RW, Moss DS. Trends Immunol. 29 374-379 (2008)
  406. Characterization of effector functions of human peptide-specific CD4+ T-cell clones for an intracellular pathogen. Klucar P, Barnes PF, Kong Y, Samten B, Tvinnereim A, Spallek R, Nepom GT, Singh M, Shams H. Hum. Immunol. 69 475-483 (2008)
  407. Definition of the peptide binding motif within DRB1*1401 restricted epitopes by peptide competition and structural modeling. James EA, Moustakas AK, Berger D, Huston L, Papadopoulos GK, Kwok WW. Mol. Immunol. 45 2651-2659 (2008)
  408. Expression of HLA-DP0401 molecules for identification of DP0401 restricted antigen specific T cells. Yang J, Huston L, Berger D, Danke NA, Liu AW, Disis ML, Kwok WW. J. Clin. Immunol. 25 428-436 (2005)
  409. The inhibitory effect of altered collagen II peptide on HLA-DRB1-restricted T-cell activation. Cheng YJ, Zhou Q, Li ZG. Scand. J. Immunol. 61 260-265 (2005)
  410. Inhibition of altered peptide ligand-mediated antagonism of human GAD65-responsive CD4+ T cells by non-antagonizable T cells. Gebe JA, Masewicz SA, Kochik SA, Reijonen H, Nepom GT. Eur. J. Immunol. 34 3337-3345 (2004)
  411. Characterization of B- and T-cell responses and HLA-DR4 binding motifs of the latex allergen Hev b 6.01 (prohevein) and its post-transcriptionally formed proteins Hev b 6.02 and Hev b 6.03. Raulf-Heimsoth M, Rozynek P, Brüning T, Rihs HP. Allergy 59 724-733 (2004)
  412. Metal-derivatized major histocompatibility complex: zeroing in on contact hypersensitivity. Loh J, Fraser J. J. Exp. Med. 197 549-552 (2003)
  413. Examination of possible structural constraints of MHC-binding peptides by assessment of their native structure within their source proteins. Schueler-Furman O, Altuvia Y, Margalit H. Proteins 45 47-54 (2001)
  414. Towards the MHC-peptide combinatorics. Kangueane P, Sakharkar MK, Kolatkar PR, Ren EC. Hum. Immunol. 62 539-556 (2001)
  415. Pocket 4 in the HLA-DRB1 antigen-binding groove: an association with atopy. Torres-Galván MJ, Quiralte J, Blanco C, Castillo R, Carrillo T, Pérez-Aciego P, Sánchez-García F. Allergy 55 398-401 (2000)
  416. The X-ray crystal structure of a Valpha2.6Jalpha38 mouse T cell receptor domain at 2.5 A resolution: alternate modes of dimerization and crystal packing. Plaksin D, Chacko S, Navaza J, Margulies DH, Padlan EA. J. Mol. Biol. 289 1153-1161 (1999)
  417. A role for the P1 anchor residue in the thermal stability of MHC class II molecule I-Ab. Tobita T, Oda M, Morii H, Kuroda M, Yoshino A, Azuma T, Kozono H. Immunol. Lett. 85 47-52 (2003)
  418. T-cell receptor contact and MHC binding residues of a major rye grass pollen allergen T-cell epitope. Burton MD, Blaher B, Suphioglu C, O'Hehir RE, Carbone FR, Rolland JM. J. Allergy Clin. Immunol. 103 255-261 (1999)
  419. CD4+ T cell repertoire on the epsilon subunit of muscle acetylcholine receptor in myasthenia gravis. Wang ZY, Okita DK, Howard JF, Conti-Fine BM. J. Neuroimmunol. 91 33-42 (1998)
  420. Fine mapping of T-cell determinants of bovine beta-lactoglobulin. Totsuka M, Ametani A, Kaminogawa S. Cytotechnology 25 101-113 (1997)
  421. Selection of self-reactive peptides within human aggrecan by use of a HLA-DRB1*0401 peptide binding motif. Boots AM, Verheijden GF, Schöningh R, van Staveren CJ, Bos E, Elewaut D, de Keyser F, Veys E, Joosten I, Rijnders AW. J. Autoimmun. 10 569-578 (1997)
  422. Differential binding of peptides substituted at putative C-terminal anchor residue to HLA-DQ8 and DQ9 differing only at beta 57. Oiso M, Nishi T, Ishikawa T, Nishimura Y, Matsushita S. Hum. Immunol. 52 47-53 (1997)
  423. A PCR-RFLP typing method for the caprine Mhc class II DRB gene. Amills M, Francino O, Sànchez A. Vet. Immunol. Immunopathol. 55 255-260 (1996)
  424. IMPIPS: the immune protection-inducing protein structure concept in the search for steric-electron and topochemical principles for complete fully-protective chemically synthesised vaccine development. Patarroyo ME, Bermúdez A, Alba MP, Vanegas M, Moreno-Vranich A, Poloche LA, Patarroyo MA. PLoS ONE 10 e0123249 (2015)
  425. Gauche(+) side-chain orientation as a key factor in the search for an immunogenic peptide mixture leading to a complete fully protective vaccine. Bermúdez A, Calderon D, Moreno-Vranich A, Almonacid H, Patarroyo MA, Poloche A, Patarroyo ME. Vaccine 32 2117-2126 (2014)
  426. In silico identification of novel protective VSG antigens expressed by Trypanosoma brucei and an effort for designing a highly immunogenic DNA vaccine using IL-12 as adjuvant. Akhoon BA, Slathia PS, Sharma P, Gupta SK, Verma V. Microb. Pathog. 51 77-87 (2011)
  427. Identification of immunogenic consensus T-cell epitopes in globally distributed influenza-A H1N1 neuraminidase. Gupta SK, Srivastava M, Akhoon BA, Smita S, Schmitz U, Wolkenhauer O, Vera J, Gupta SK. Infect. Genet. Evol. 11 308-319 (2011)
  428. Natural selection coupled with intragenic recombination shapes diversity patterns in the major histocompatibility complex class II genes of the giant panda. Chen YY, Zhang YY, Zhang HM, Ge YF, Wan QH, Fang SG. J. Exp. Zool. B Mol. Dev. Evol. 314 208-223 (2010)
  429. SKDM human leukocyte antigen (HLA) tool: A comprehensive HLA and disease associations analysis software. Kanterakis S, Magira E, Rosenman KD, Rossman M, Talsania K, Monos DS. Hum. Immunol. 69 522-525 (2008)
  430. The immune function of MHC class II molecules mutated in the putative superdimer interface. Hayball JD, Lake RA. Mol. Cell. Biochem. 273 1-9 (2005)
  431. Involvement of zinc in the binding of Mycoplasma arthritidis-derived mitogen to the proximity of the HLA-DR binding groove regardless of histidine 81 of the beta chain. Etongué-Mayer P, Langlois MA, Ouellette M, Li H, Younes S, Al-Daccak R, Mourad W. Eur. J. Immunol. 32 50-58 (2002)
  432. Association of the amino acid motifs of BoLA-DRB3 alleles with mastitis pathogens in Japanese Holstein cows Yoshida T, Mukoyama H, Furuta H, Kondo Y, Takeshima Sn, Aida Y, Kosugiyama M, Tomogane H. Anim. Sci. J. 80 510-519 (2009)
  433. A small number of residues in the class II molecule I-Au confer the ability to bind the myelin basic protein peptide Ac1-11. Pearson CI, Gautam AM, Rulifson IC, Liblau RS, McDevitt HO. Proc. Natl. Acad. Sci. U.S.A. 96 197-202 (1999)
  434. New ligands for HLA DRB1*0301 by random selection of favourable amino acids ranked by competition studies with undecapeptide amide sublibraries. Jung C, Kalbus M, Fleckenstein B, Melms A, Jung G, Wiesmüller KH. J. Immunol. Methods 219 139-149 (1998)
  435. Analysis of HLA class II and TAP alleles in Japanese patients with psoriasis vulgaris. Saeki H, Kuwata S, Nakagawa H, Asahina A, Tamaki K, Shibata Y, Juji T. Hum. Immunol. 59 503-511 (1998)
  436. Modulation of peptide-dependent allospecific epitopes on HLA-DR4 molecules by HLA-DM. Drover S, Kovats S, Masewicz S, Blum JS, Nepom GT. Hum. Immunol. 59 77-86 (1998)
  437. Mtv-1 superantigen trafficks independently of major histocompatibility complex class II directly to the B-cell surface by the exocytic pathway. Grigg ME, McMahon CW, Morkowski S, Rudensky AY, Pullen AM. J. Virol. 72 2577-2588 (1998)
  438. A recombinant single-chain human class II MHC molecule (HLA-DR1) as a covalently linked heterotrimer of alpha chain, beta chain, and antigenic peptide, with immunogenicity in vitro and reduced affinity for bacterial superantigens. Zhu X, Bavari S, Ulrich R, Sadegh-Nasseri S, Ferrone S, McHugh L, Mage M. Eur. J. Immunol. 27 1933-1941 (1997)
  439. Molecular modeling of a T-cell receptor bound to a major histocompatibility complex molecule: implications for T-cell recognition. Almagro JC, Vargas-Madrazo E, Lara-Ochoa F, Horjales E. Protein Sci. 4 1708-1717 (1995)
  440. The Thermodynamic Mechanism of Peptide-MHC Class II Complex Formation Is a Determinant of Susceptibility to HLA-DM. Ferrante A, Templeton M, Hoffman M, Castellini MJ. J. Immunol. 195 1251-1261 (2015)
  441. Theoretical analysis of the neuraminidase epitope of the Mexican A H1N1 influenza strain, and experimental studies on its interaction with rabbit and human hosts. Loyola PK, Campos-Rodríguez R, Bello M, Rojas-Hernández S, Zimic M, Quiliano M, Briz V, Muñoz-Fernández MA, Tolentino-López L, Correa-Basurto J. Immunol. Res. 56 44-60 (2013)
  442. Peptide binding to HLA-DP proteins at pH 5.0 and pH 7.0: a quantitative molecular docking study. Patronov A, Dimitrov I, Flower DR, Doytchinova I. BMC Struct. Biol. 12 20 (2012)
  443. (E)-alkene and ethylene isosteres substantially alter the hydrogen-bonding network in class II MHC A(q)/glycopeptide complexes and affect T-cell recognition. Andersson IE, Batsalova T, Haag S, Dzhambazov B, Holmdahl R, Kihlberg J, Linusson A. J. Am. Chem. Soc. 133 14368-14378 (2011)
  444. Identification of the minimal glycopeptide core recognized by T cells in a model for rheumatoid arthritis. Holm L, Kjellén P, Holmdahl R, Kihlberg J. Bioorg. Med. Chem. 13 473-482 (2005)
  445. Emerging principles for the design of promiscuous HLA-DR-restricted peptides: an example from the major bee venom allergen. Texier C, Pouvelle-Moratille S, Buhot C, Castelli FA, Pecquet C, Ménez A, Leynadier F, Maillère B. Eur. J. Immunol. 32 3699-3707 (2002)
  446. Types of inter-atomic interactions at the MHC-peptide interface: identifying commonality from accumulated data. Adrian PE, Rajaseger G, Mathura VS, Sakharkar MK, Kangueane P. BMC Struct. Biol. 2 2 (2002)
  447. Synthesis of a C-glycoside analogue of beta-D-galactosyl hydroxynorvaline and its use in immunological studies. Wellner E, Gustafsson T, Bäcklund J, Holmdahl R, Kihlberg J. Chembiochem 1 272-280 (2000)
  448. CD4 TCRBV CDR3 analysis in prevalent SLE cases from two ethnic groups. Fraser PA, Lu LY, DeCeulaer K, Schur PH, Fici D, Awdeh Z, Ding WZ, Levitan E, Lew R, Uko G, Gonzalez C. Lupus 8 311-319 (1999)
  449. Conserved structural features between HLA-DO beta and -DR beta. Thibodeau J, Lavoie PM, Samaan A, Corre JP, Sékaly RP, Cazenave PA. Mol. Immunol. 35 885-893 (1998)
  450. Novel physiological functions of cathepsins B and L on antigen processing and osteoclastic bone resorption. Katunuma N, Matsunaga Y, Matsui A, Kakegawa H, Endo K, Inubushi T, Saibara T, Ohba Y, Kakiuchi T. Adv. Enzyme Regul. 38 235-251 (1998)
  451. A peptide-binding assay for the disease-associated HLA-DQ8 molecule. Straumfors A, Johansen BH, Vartdal F, Sollid LM, Thorsby E, Buus S. Scand. J. Immunol. 47 561-567 (1998)
  452. Response of CD4+ T cells from myasthenic patients and healthy subjects of biosynthetic and synthetic sequences of the nicotinic acetylcholine receptor. Diethelm-Okita B, Wells GB, Kuryatov A, Okita D, Howard J, Lindstrom JM, Conti-Fine BM. J. Autoimmun. 11 191-203 (1998)
  453. Antigen-specific inhibition of CD4+ T-cell responses to beta-lactoglobulin by its single amino acid-substituted mutant form through T-cell receptor antagonism. Totsuka M, Furukawa S, Sato E, Ametani A, Kaminogawa S. Cytotechnology 25 115-126 (1997)
  454. Intact proteins can bind to class II histocompatibility molecules with high affinity. Runnels HA, Weber DA, Moore JC, Westerman LE, Jensen PE. Mol. Immunol. 34 471-480 (1997)
  455. Effect of polymorphism of the HLA-DPA1 chain on presentation of antigenic peptides. Gaston JS, Goodall JC, Young JL, Young SP. Hum. Immunol. 54 40-47 (1997)
  456. Diversity and evolution of the DRB1*03 family: description of DRB1*03022,*0307,*0308. Ellis JM, Steiner N, Wang J, Tang TT, Hurley CK. Tissue Antigens 49 41-45 (1997)
  457. Determination of the allele-specific antigen-binding site on I-Ak and I-Ab molecules. Itoh Y, Kajino K, Ogasawara K, Katoh M, Namba K, Takami K, Iwabuchi K, Braunstein NS, Onoé K. Eur. J. Immunol. 26 1314-1321 (1996)
  458. Recognition of altered self major histocompatibility complex molecules modulated by specific peptide interactions. Nepom GT, Ou D, Lybrand TP, DeWeese C, Domeier ME, Buckner JH, Mitchell LA, Tingle AJ. Eur. J. Immunol. 26 949-952 (1996)
  459. Periodic variation in side-chain polarities of T-cell antigenic peptides correlates with their structure and activity. Cornette JL, Margalit H, Berzofsky JA, DeLisi C. Proc. Natl. Acad. Sci. U.S.A. 92 8368-8372 (1995)
  460. Differences in processing of an autoantigen by DR4:Dw4.2 and DR4:Dw14.2 antigen-presenting cells. Nicolle MW, Hawke S, Willcox N, Vincent A. Eur. J. Immunol. 25 2119-2122 (1995)
  461. Differences in peptide binding of DR11 and DR13 microvariants demonstrate the power of minor variation in generating DR functional diversity. Hurley CK, Steiner N. Hum. Immunol. 43 101-112 (1995)
  462. Purification and characterization of endogenous peptides extracted from HLA-DR isolated from the spleen of a patient with rheumatoid arthritis. Gordon RD, Young JA, Rayner S, Luke RW, Crowther ML, Wordsworth P, Bell J, Hassall G, Evans J, Hinchliffe SA. Eur. J. Immunol. 25 1473-1476 (1995)
  463. A new HLA-DRB1*1116 allele sharing DR13 and DR11 sequence motifs. Thonnard J, Blaimond B, Heusterspreut M, Straetmans N, Philippe M. Tissue Antigens 46 124-127 (1995)
  464. Red Queen Processes Drive Positive Selection on Major Histocompatibility Complex (MHC) Genes. Ejsmond MJ, Radwan J. PLoS Comput. Biol. 11 e1004627 (2015)
  465. Aneurysmal lesions of patients with abdominal aortic aneurysm contain clonally expanded T cells. Lu S, White JV, Lin WL, Zhang X, Solomides C, Evans K, Ntaoula N, Nwaneshiudu I, Gaughan J, Monos DS, Oleszak EL, Platsoucas CD. J. Immunol. 192 4897-4912 (2014)
  466. A novel family of human leukocyte antigen class II receptors may have its origin in archaic human species. Temme S, Zacharias M, Neumann J, Wohlfromm S, König A, Temme N, Springer S, Trowsdale J, Koch N. J. Biol. Chem. 289 639-653 (2014)
  467. Small molecule inhibitor of antigen binding and presentation by HLA-DR2b as a therapeutic strategy for the treatment of multiple sclerosis. Ji N, Somanaboeina A, Dixit A, Kawamura K, Hayward NJ, Self C, Olson GL, Forsthuber TG. J. Immunol. 191 5074-5084 (2013)
  468. The HLA-DRB1 Polymorphism is Associated With Atopic Dermatitis, but not Egg Allergy in Korean Children. Park H, Ahn K, Park MH, Lee SI. Allergy Asthma Immunol Res 4 143-149 (2012)
  469. Evolutionary genetics of MHC class II beta genes in the brown hare, Lepus europaeus. Smith S, de Bellocq JG, Suchentrunk F, Schaschl H. Immunogenetics 63 743-751 (2011)
  470. Characterization of the MHC class II α-chain gene in ducks. Ren L, Yang Z, Wang T, Sun Y, Guo Y, Zhang Z, Fei J, Bao Y, Qin T, Wang J, Huang Y, Hu X, Zhao Y, Li N. Immunogenetics 63 667-678 (2011)
  471. The modulation of adaptive immune responses by bacterial zwitterionic polysaccharides. Stephen TL, Groneck L, Kalka-Moll WM. Int J Microbiol 2010 917075 (2010)
  472. HLA homology within the C5 domain promotes peptide binding by HIV type 1 gp120. Cadogan M, Austen B, Heeney JL, Dalgleish AG. AIDS Res. Hum. Retroviruses 24 845-855 (2008)
  473. Vaccination with a MHC class II peptide in Alum and inactive pertussis strongly ameliorates clinical MG in C57BL/6 mice. Oshima M, Maruta T, Ohtani M, Deitiker PR, Mosier D, Atassi MZ. J. Neuroimmunol. 171 8-16 (2006)
  474. Threonine at position 6 is not essential for the immunosuppressive activity of HLA-DQ(beta164-172)-hexapeptide. Stefanowicz P, Boratyński PJ, Staszewska A, Wilczyński A, Zimecki M, Szewczuk Z. Mol. Immunol. 41 911-917 (2004)
  475. Determination of the peptide binding motif and high-affinity ligands for HLA-DQ4 using synthetic peptide libraries. Volz T, Schwarz G, Fleckenstein B, Schepp CP, Haug M, Roth J, Wiesmüller KH, Dannecker GE. Hum. Immunol. 65 594-601 (2004)
  476. Modeling MHC class II molecules and their bound peptides as expressed at the cell surface. Simon A, Simon I, Rajnavölgyi E. Mol. Immunol. 38 681-687 (2002)
  477. T-helper epitopes identified within the E6 transforming protein of cervical cancer-associated human papillomavirus type 16. Azoury-Ziadeh R, Herd K, Fernando GJ, Frazer IH, Tindle RW. Viral Immunol. 12 297-312 (1999)
  478. New conformationally restricted analog of the immunosuppressory mini-domain of HLA-DQ and its biological properties. Szewczuk Z, Wilczyński A, Dyba M, Petry I, Siemion IZ, Wieczorek Z. Peptides 21 1849-1858 (2000)
  479. Recognition of contiguous allele-specific peptide elements in the rubella virus E1 envelope protein. Nepom GT, Domeier ME, Ou D, Kovats S, Mitchell LA, Tingle AJ. Vaccine 15 648-652 (1997)
  480. The impact of DR3 microvariation on peptide binding: the combinations of specific DR beta residues critical to binding differ for different peptides. Posch PE, Hurley CK, Geluk A, Ottenhoff TH. Hum. Immunol. 49 96-105 (1996)
  481. Novel in silico tools for designing peptide-based subunit vaccines and immunotherapeutics. Dhanda SK, Usmani SS, Agrawal P, Nagpal G, Gautam A, Raghava GPS. Brief. Bioinformatics 18 467-478 (2017)
  482. Structure and polymorphism of the major histocompatibility complex class II region in the Japanese Crested Ibis, Nipponia nippon. Taniguchi Y, Matsumoto K, Matsuda H, Yamada T, Sugiyama T, Homma K, Kaneko Y, Yamagishi S, Iwaisaki H. PLoS ONE 9 e108506 (2014)
  483. Association of human leukocyte antigen DQB1 and DRB1 alleles with chronic hepatitis B. Doganay L, Fejzullahu A, Katrinli S, Yilmaz Enc F, Ozturk O, Colak Y, Ulasoglu C, Tuncer I, Dinler Doganay G. World J. Gastroenterol. 20 8179-8186 (2014)
  484. Disruption of hydrogen bonds between major histocompatibility complex class II and the peptide N-terminus is not sufficient to form a human leukocyte antigen-DM receptive state of major histocompatibility complex class II. Schulze MS, Anders AK, Sethi DK, Call MJ. PLoS ONE 8 e69228 (2013)
  485. Increased synapse formation obtained by T cell epitopes containing a CxxC motif in flanking residues convert CD4+ T cells into cytolytic effectors. Carlier VA, VanderElst L, Janssens W, Jacquemin MG, Saint-Remy JM. PLoS ONE 7 e45366 (2012)
  486. Independent evolution of functional MHC class II DRB genes in New World bat species. Schad J, Voigt CC, Greiner S, Dechmann DK, Sommer S. Immunogenetics 64 535-547 (2012)
  487. Molecular modeling of class I and II alleles of the major histocompatibility complex in Salmo salar. Cárdenas C, Bidon-Chanal A, Conejeros P, Arenas G, Marshall S, Luque FJ. J. Comput. Aided Mol. Des. 24 1035-1051 (2010)
  488. Genetic determinants of type 1 diabetes: immune response genes. Kumar N, Kaur G, Mehra N. Biomark Med 3 153-173 (2009)
  489. Lymphotoxin alpha LTA+496C allele is a risk factor for periodontitis in patients with coronary artery disease. Palikhe A, Lokki ML, Pussinen PJ, Paju S, Ahlberg J, Asikainen S, Seppänen M, Valtonen V, Nieminen MS, Sinisalo J. Tissue Antigens 71 530-537 (2008)
  490. The relative energetic contributions of dominant P1 pocket versus hydrogen bonding interactions to peptide:class II stability: implications for the mechanism of DM function. Bandyopadhyay A, Arneson L, Beeson C, Sant AJ. Mol. Immunol. 45 1248-1257 (2008)
  491. The Th1 immune response against HIV-1 Gag p24-derived peptides in mice expressing HLA-A02.01 and HLA-DR1. Pajot A, Schnuriger A, Moris A, Rodallec A, Ojcius DM, Autran B, Lemonnier FA, Lone YC. Eur. J. Immunol. 37 2635-2644 (2007)
  492. Association between hepatic alveolar echinococcosis and frequency of human leukocyte antigen class I and II alleles in Turkish patients. Aydinli B, Pirim I, Polat KY, Gursan N, Atamanalp SS, Ezer M, Donmez R. Hepatol. Res. 37 806-810 (2007)
  493. Sea bass (Dicentrarchus labrax) invariant chain and class II major histocompatibility complex: sequencing and structural analysis using 3D homology modelling. Silva DS, Reis MI, Nascimento DS, do Vale A, Pereira PJ, dos Santos NM. Mol. Immunol. 44 3758-3776 (2007)
  494. HLA-DQB1*0317 is a novel allele with an unusual DR-DQ haplotype. Chu CC, Lin CY, Trejaut JA, Wu MM, Lin M. Tissue Antigens 69 370-372 (2007)
  495. Prediction of CD4(+) T cell epitopes restricted to HLA-DP4 molecules. Busson M, Castelli FA, Wang XF, Cohen WM, Charron D, Ménez A, Maillère B. J. Immunol. Methods 317 144-151 (2006)
  496. Comparative molecular and three-dimensional analysis of the peptide-MHC II binding region in both human and Aotus MHC-DRB molecules confirms their usefulness in antimalarial vaccine development. Patarroyo ME, Cifuentes G, Baquero J. Immunogenetics 58 598-606 (2006)
  497. Expressed MHC class II genes in sea otters (Enhydra lutris) from geographically disparate populations. Bowen L, Aldridge BM, Miles AK, Stott JL. Tissue Antigens 67 402-408 (2006)
  498. T-cell epitopes of the La/SSB autoantigen: prediction based on the homology modeling of HLA-DQ2/DQ7 with the insulin-B peptide/HLA-DQ8 complex. Kosmopoulou A, Vlassi M, Stavrakoudis A, Sakarellos C, Sakarellos-Daitsiotis M. J Comput Chem 27 1033-1044 (2006)
  499. The tortuous journey of a biochemist to immunoland and what he found there. Strominger JL. Annu. Rev. Immunol. 24 1-31 (2006)
  500. Functionally divergent T lymphocyte responses induced by modification of a self-peptide from a tumor-associated antigen. Hess AD, Thoburn CJ, Miura Y, Bright EC. Clin. Immunol. 114 307-319 (2005)
  501. Peptide motif for the rat MHC class II molecule RT1.Da: similarities to the multiple sclerosis-associated HLA-DRB1*1501 molecule. Duyar H, Dengjel J, de Graaf KL, Wiesmüller KH, Stevanović S, Weissert R. Immunogenetics 57 69-76 (2005)
  502. Identification of two new HLA-DRB1 alleles: HLA-DRB1*1350 and DRB1*140502. Chen ZX, Tsan SG, Dang CW, Chu CC, Lin M, Lee YJ. Tissue Antigens 64 300-303 (2004)
  503. Crystallization and preliminary crystallographic analysis of Mycoplasma arthritidis-derived mitogen complexed with peptide/MHC class II antigen. Zhao Y, Li Z, Drozd S, Guo Y, Stack R, Hauer C, Li H. Acta Crystallogr. D Biol. Crystallogr. 60 353-356 (2004)
  504. MSP-1 malaria pseudopeptide analogs: biological and immunological significance and three-dimensional structure. Lozano JM, Alba MP, Vanegas M, Silva Y, Torres-Castellanos JL, Patarroyo ME. Biol. Chem. 384 71-82 (2003)
  505. The correlation between ovomucoid-derived peptides, human leucocyte antigen class II molecules and T cell receptor-complementarity determining region 3 compositions in patients with egg-white allergy. Suzuki K, Inoue R, Sakaguchi H, Aoki M, Kato Z, Kaneko H, Matsushita S, Kondo N. Clin. Exp. Allergy 32 1223-1230 (2002)
  506. Autoreactivity in collagen-induced arthritis of rats: a potential role for T cell responses to self MHC peptides. Catchpole B, Ward FJ, Hamblin AS, Staines NA. J. Autoimmun. 18 271-280 (2002)
  507. Identification of a novel DR4 allele, DRB1*0442. Dunn TA, Iglehart BA, Leffell MS. Tissue Antigens 58 198-200 (2001)
  508. Cross-restriction of a T cell clone to HLA-DR alleles associated with rheumatoid arthritis: clues to arthritogenic peptide motifs. Hawke S, Matsuo H, Nicolle M, Wordsworth P, Corlett L, Spack E, Deshpande S, Driscoll PC, Willcox N. Arthritis Rheum. 42 1040-1050 (1999)
  509. Patterns of variability at the major histocompatibility class I and class II loci in populations of the endangered cyprinid Ladigesocypris ghigii Moutou KA, Mamuris Z, Firme T, Kontou M, Sarafidou T, Stoumboudi MT. Conserv. Genet. 12 1159-1171 (2011)
  510. Correlation between HLA-DR sequence polymorphisms and rheumatoid factor production. Weyand CM, Goronzy JJ. Ann. N. Y. Acad. Sci. 815 353-356 (1997)
  511. Importance of HLA-DRB1 molecular matching based on three-dimensional structure in cadaveric renal transplantation: a trial of new criteria for recipient and donor selection. Sada M, Takahara S, Tada M, Hatori M, Wang JD, Okuyama A, Tsuji T. Transplant. Proc. 29 1440-1442 (1997)
  512. A new DRB1 allele (DRB1*1125) sharing DR11 and DR8 sequence motifs. Perrier P, Reveillère C, Schuhmacher A. Tissue Antigens 49 84-87 (1997)
  513. Increased responsiveness of rheumatoid factor-producing B cells in seronegative and seropositive rheumatoid arthritis. He X, Zhong W, McCarthy TG, Weyand CM, Goronzy JJ. Arthritis Rheum. 39 1499-1506 (1996)
  514. The MHC class II-associated invariant chain-derived peptide clip binds to the peptide-binding groove of class II molecules. Wu S, Gorski J. Mol. Immunol. 33 371-377 (1996)
  515. Spatial patterns of immunogenetic and neutral variation underscore the conservation value of small, isolated American badger populations. Rico Y, Ethier DM, Davy CM, Sayers J, Weir RD, Swanson BJ, Nocera JJ, Kyle CJ. Evol Appl 9 1271-1284 (2016)
  516. Matched Peptides: Tuning Matched Molecular Pair Analysis for Biopharmaceutical Applications. Fuchs JE, Wellenzohn B, Weskamp N, Liedl KR. J Chem Inf Model 55 2315-2323 (2015)
  517. Predicting peptide vaccine candidates against H1N1 influenza virus through theoretical approaches. Bello M, Campos-Rodriguez R, Rojas-Hernandez S, Contis-Montes de Oca A, Correa-Basurto J. Immunol. Res. 62 3-15 (2015)
  518. Association of HLA-DRB1 with Sarcoidosis Susceptibility and Progression in African Americans. Levin AM, Adrianto I, Datta I, Iannuzzi MC, Trudeau S, Li J, Drake WP, Montgomery CG, Rybicki BA. Am. J. Respir. Cell Mol. Biol. 53 206-216 (2015)
  519. A novel method to measure HLA-DM-susceptibility of peptides bound to MHC class II molecules based on peptide binding competition assay and differential IC(50) determination. Yin L, Stern LJ. J. Immunol. Methods 406 21-33 (2014)
  520. Editorial Computational modelling and inhibitor risk: predicting the future? Hart DP. Haemophilia 20 155-157 (2014)
  521. Rationally designed mutations convert complexes of human recombinant T cell receptor ligands into monomers that retain biological activity. Huan JY, Meza-Romero R, Mooney JL, Chou YK, Edwards DM, Rich C, Link JM, Vandenbark AA, Bourdette DN, Bächinger HP, Burrows GG. J Chem Technol Biotechnol 80 2-12 (2005)
  522. DRB1*12:01 presents a unique subset of epitopes by preferring aromatics in pocket 9. Chow IT, James EA, Tan V, Moustakas AK, Papadopoulos GK, Kwok WW. Mol. Immunol. 50 26-34 (2012)
  523. HLA-DP2 binding prediction by molecular dynamics simulations. Doytchinova I, Petkov P, Dimitrov I, Atanasova M, Flower DR. Protein Sci. 20 1918-1928 (2011)
  524. The CD4+ T-cell epitope-binding register is a critical parameter when generating functional HLA-DR tetramers with promiscuous peptides. Cecconi V, Moro M, Del Mare S, Sidney J, Bachi A, Longhi R, Sette A, Protti MP, Dellabona P, Casorati G. Eur. J. Immunol. 40 1603-1616 (2010)
  525. Major histocompatibility complex class II molecule-human immunodeficiency virus peptide analysis using a microarray chip. Gaseitsiwe S, Valentini D, Ahmed R, Mahdavifar S, Magalhaes I, Zerweck J, Schutkowski M, Gautherot E, Montero F, Ehrnst A, Reilly M, Maeurer M. Clin. Vaccine Immunol. 16 567-573 (2009)
  526. Variations in the electrostatic landscape of class II human leukocyte antigen molecule induced by modifications in the myelin basic protein peptide: a theoretical approach. Agudelo WA, Galindo JF, Ortiz M, Villaveces JL, Daza EE, Patarroyo ME. PLoS ONE 4 e4164 (2009)
  527. HLA-DPbeta chain may confer the susceptibility to hepatitis C virus-associated hypertrophic cardiomyopathy. Shichi D, Matsumori A, Naruse TK, Inoko H, Kimura A. Int. J. Immunogenet. 35 37-43 (2008)
  528. Conformation of MHC class II I-A(g7) is sensitive to the P9 anchor amino acid in bound peptide. Gardiner A, Richards KA, Sant AJ, Arneson LS. Int. Immunol. 19 1103-1113 (2007)
  529. A theoretical analysis of HLA-DRbeta1*0301-CLIP complex using the first three multipolar moments of the electrostatic field. Balbín A, Cárdenas C, Villaveces JL, Patarroyo ME. Biochimie 88 1307-1311 (2006)
  530. Wave function analysis of MHC-peptide interactions. Cárdenas C, Obregón M, Balbín A, Villaveces JL, Patarroyo ME. J. Mol. Graph. Model. 25 605-615 (2007)
  531. Novel HLA-DRB1*1370 allele identified in a cord blood donor and her mother. Horn PA, Zingsem J, Eckstein R, Blasczyk R. Tissue Antigens 67 345-347 (2006)
  532. Replacement of the membrane proximal region of I-A(d) MHC class II molecule with I-E-derived sequences promotes production of an active and stable soluble heterodimer without altering peptide-binding specificity. Chaves FA, Hou P, Wu S, Sant AJ. J. Immunol. Methods 300 74-92 (2005)
  533. Identification of a new HLA-DRB1 allele in three members of an Italian family. Garino E, Berrino M, Mazzola G, Boccadoro M, Bruno B, Bertinetto F, Bertola L, Caropreso P, Frisaldi E, Marin F, Panniello ML, Tondat F, Dall'Omo AM. Tissue Antigens 64 210-212 (2004)
  534. Truncation of the neuritogenic peptide bP2(60-70) results in the generation of altered peptide ligands with the potential to interfere with T cell activation. Offenhäusser M, Herr AS, Hartkamp J, Wauben M, Magnus T, Grauer O, Seubert S, Weishaupt A, Toyka KV, Gold R, Troppmair J. J. Neuroimmunol. 129 97-105 (2002)
  535. Evidences of conformational changes in class II Major Histocompatibility Complex molecules that affect the immunogenicity. Neveu R, Auriault C, Angyalosi G, Georges B. Mol. Immunol. 38 661-667 (2002)
  536. HLA-DQA1 allele typing by nonisotopic PCR-LIS-SSCP. Abba MC, Gómez MA, Golijow CD. Braz. J. Med. Biol. Res. 34 867-869 (2001)
  537. Polymorphism of human HLA-DRB1 antigens generated by genetic exchange between DR2 (DRB1*15011) and DR6 (DRB1*1405) alleles: a novel DRB1 allele (DRB1*1437) identified in a Paiwan tribe member of Taiwan. Wu S, Shiao YM, Lai CY, Lai SM, Chen SP, Sidebottom DA, Hildebrand WH, Tilanus MG, Chou FC, Tsai MF. Tissue Antigens 57 384-387 (2001)
  538. Genetic susceptibility and the link between cat exposure and rheumatoid arthritis. Penglis PS, Bond C, Humphreys I, McCluskey J, Cleland LG. Semin. Arthritis Rheum. 30 111-120 (2000)
  539. Structural diversity of human class II histocompatibility molecules induced by peptide ligands. Georges B, Loing E, Neveu R, Melnyk O, Gras-Masse H, Auriault C. FEBS Lett. 481 249-254 (2000)
  540. HLA-DRB1 leprogenic motifs in nigerian population groups. Uko GP, Lu LY, Asuquo MA, Fici D, Mahan S, Awdeh Z, Udim ER, Ding W, Umana U, Adewole T, Fraser PA. Clin. Exp. Immunol. 118 56-62 (1999)
  541. T cell responses to D-penicillamine in drug-induced myasthenia gravis: recognition of modified DR1:peptide complexes. Hill M, Moss P, Wordsworth P, Newsom-Davis J, Willcox N. J. Neuroimmunol. 97 146-153 (1999)
  542. Prevention of infection of influenza virus in DQ6 mice, a human model, by a peptide vaccine prepared according to the cassette theory. Matsuki N, Ogasawara K, Takami K, Namba K, Takahashi A, Fukui Y, Sasazuki T, Iwabuchi K, Good RA, Onoé K. Vaccine 17 1161-1168 (1999)
  543. Residue 67 in the DRbeta1*0101 and DRbeta1*0103 chains strongly influences antigen presentation and DR-peptide molecular complex conformation. L'Faqihi FE, Praud C, Yassine-Diab B, Enault G, Lakhdar-Ghazal F, de Préval C, Coppin H. Tissue Antigens 51 10-19 (1998)
  544. A murine monoclonal antibody (928) recognizing a new epitope formed with a combination of HLA-DPA1*0201 and DPB1*0301 gene products. Kishi H, Okumura A, Tong JJ, Sugiyama E, Matsuno H, Minowada J, Kanai T, Nishimura Y, Muraguchi A. Hum. Immunol. 56 114-124 (1997)
  545. The relative importance of individual DR binding motif positions as defined by peptide anchor analysis of influenza hemagglutinin peptide 306-318 and human myelin basic protein peptide 152-165 binding to several DR molecules: definition of a common extended DR binding motif. Posch PE, Hastings AE, Rosen-Bronson S, Richert JR, Hurley CK. Eur. J. Immunol. 26 1884-1891 (1996)
  546. Binding of mutated Ras- and p53-derived peptides to HLA-DR molecules. Murakami S, Yokomizo H, Matsushita S, Ogawa M, Nishimura Y. Immunol. Lett. 49 149-153 (1996)
  547. Covalently linked ligand stabilizes expression of heterodimeric receptor. Wilson IA. Structure 2 561-562 (1994)
  548. sNebula, a network-based algorithm to predict binding between human leukocyte antigens and peptides. Luo H, Ye H, Ng HW, Sakkiah S, Mendrick DL, Hong H. Sci Rep 6 32115 (2016)
  549. Development and validation of an epitope prediction tool for swine (PigMatrix) based on the pocket profile method. Gutiérrez AH, Martin WD, Bailey-Kellogg C, Terry F, Moise L, De Groot AS. BMC Bioinformatics 16 290 (2015)
  550. Genetic characterization of MHC class II DQB exon 2 variants in gayal (Bos frontalis). Sun Y, Xi D, Li G, Hao T, Chen Y, Yang Y. Biotechnol. Biotechnol. Equip. 28 827-833 (2014)
  551. An unstable Th epitope of P. falciparum fosters central memory T cells and anti-CS antibody responses. Parra-López CA, Bernal-Estévez D, Yin L, Vargas LE, Pulido-Calixto C, Salazar LM, Calvo-Calle JM, Stern LJ. PLoS ONE 9 e100639 (2014)
  552. A human-specific allelic group of the MHC DRB1 gene in primates. Yasukochi Y, Satta Y. J Physiol Anthropol 33 14 (2014)
  553. Association of BoLA DRB3 alleles with variability in immune response among the crossbred cattle vaccinated for foot-and-mouth disease (FMD). Gowane GR, Sharma AK, Sankar M, Narayanan K, Das B, Subramaniam S, Pattnaik B. Res. Vet. Sci. 95 156-163 (2013)
  554. Trans heterodimer between two non-arthritis-associated HLA alleles can predispose to arthritis in humanized mice. Behrens M, Papadopoulos GK, Moustakas A, Smart M, Luthra H, David CS, Taneja V. Arthritis Rheum. 63 1552-1561 (2011)
  555. The HLA-DP2 protein binds the immunodominant epitope from myelin basic protein, MBP85-99, with high affinity. Hansen BE, Nielsen CH, Madsen HO, Ryder LP, Jakobsen BK, Svejgaard A. Tissue Antigens 77 229-234 (2011)
  556. The predicted protein structures of the novel DRB1*0717 and DRB1*0701 are highly related. Wurm M, Tischer S, Immenschuh S, Blasczyk R, Eiz-Vesper B. Tissue Antigens 74 460-462 (2009)
  557. A novel HLA-DRB1 allele, DRB*1611, is identified in two Taiwanese individuals. Chu CC, Lee HL, Lin M. Tissue Antigens 74 175-176 (2009)
  558. Letter Antiglycoprotein IIb-IIIa autoantibody in a patient with immune thrombocytopenia after cord blood transplantation. Nomura S, Ishii K, Inami N, Matsuzaki T, Yamaoka M, Urase F, Maeda Y, Fukuhara S. Clin. Appl. Thromb. Hemost. 15 123-124 (2009)
  559. Identification of two novel HLA-DRB1 alleles, HLA-DRB1*1214 and HLA-DRB1*1215, in two Taiwanese individuals. Lee HL, Chu CC, Trejaut JA, Yang KL, Lin M. Int. J. Immunogenet. 35 423-426 (2008)
  560. Identification of a novel HLA-DRB1 allele, DRB1*116502, by sequence-based typing in an African-American individual. Serov Y, Hommel-Berrey G, Lobashevsky A. Tissue Antigens 71 489-490 (2008)
  561. Identification of a novel HLA-DRB1*09 allele, DRB1*0904, in the Korean population, by sequence-based typing. Song CH, Baek JY, Heo YS, Kwack K, Kwon OJ. Tissue Antigens 67 179-180 (2006)
  562. A five-residue HIV envelope helper T cell determinant: does this peptide-MHC interaction leave the binding groove half empty? Lockey TD, Surman S, Brown S, Slobod KS, Coleclough C, Doherty PC, Hurwitz JL. AIDS Res. Hum. Retroviruses 18 1141-1144 (2002)
  563. Structural analysis of two HLA-DR-presented autoantigenic epitopes: crucial role of peripheral but not central peptide residues for T-cell receptor recognition. De Oliveira DB, Harfouch-Hammoud E, Otto H, Papandreou NA, Stern LJ, Cohen H, Boehm BO, Bach J, Caillat-Zucman S, Walk T, Jung G, Eliopoulos E, Papadopoulos GK, van Endert PM. Mol. Immunol. 37 813-825 (2000)
  564. A simple screening method for detecting bindings between oligopeptides and HLA-DR molecules on filter papers: possible application for mapping of putative helper T-cell epitopes on MSP1 of Plasmodium falciparum. Fu J, Hato M, Igarashi K, Suzuki T, Matsuoka H, Ishii A, Leafasia JL, Chinzei Y, Ohta N. Microbiol. Immunol. 44 249-257 (2000)
  565. Tetrapeptide derived inhibitors of complexation of a class II MHC: fully unnatural ligands. Jones AB, Acton JJ, Adams AD, Yuen W, Nichols EA, Schwartz CD, Wicker LS, Hermes JD. Bioorg. Med. Chem. Lett. 9 2115-2118 (1999)
  566. Iterative stepwise discriminant analysis: a meta-algorithm for detecting quantitative sequence motifs. Mallios RR. J. Comput. Biol. 5 703-711 (1998)
  567. Point mutation of a rubella virus E1 protein T-cell epitope by substitution of single amino acid reversed the restrictive HLA-DR polymorphism: a possible mechanism maintaining HLA polymorphism. Ou D, Mitchell LA, Décarie D, Tingle AJ, Lacroix M, Zrein M. Viral Immunol. 11 93-102 (1998)
  568. Proposal for a new classification of HLA-DR alleles based on electric charges of pockets of amino acid residues. Busson M, Djoulah S, Karsenty E, Bleux H, Bouteiller AM, Charron D. Transplant. Proc. 30 2855-2856 (1998)
  569. The N-terminal six residues of peptide core sequences suffice for binding to HLA-DR4 (DRB1*0405) and DR9 (DRB1*0901) molecules. Matsushita S, Fujisao S, Nishimura Y. Immunol. Lett. 58 89-93 (1997)
  570. Peptide binding to mixed isotype Abeta(d)Ealpha(d) class II histocompatibility molecules. Moore JC, Zauderer M, Natarajana K, Jensen PE. Mol. Immunol. 34 145-155 (1997)
  571. Substitutions in the HLA-DR alpha chain differentially affect DR7-restricted T-cell recognition of rabies virus antigen. Fu XT, Saibara T, Karr RW, Celis E. Hum. Immunol. 45 111-116 (1996)
  572. Binding of ALA-substituted analogs of HA306-320 to DR1101, DR1301, and DR0402 molecules: correlation of DR-peptide interactions with recognition by a single TCR. Zeliszewski D, Golvano JJ, Gaudebout P, Dorval I, Borras-Cuesta F, Sterkers G. Hum. Immunol. 50 61-69 (1996)
  573. A biological function for the XP motif within the N terminus of major histocompatibility complex class II-associated peptides. Breloer M, Ehrlich S, Fleischer B, von Bonin A. Eur. J. Immunol. 26 1825-1829 (1996)
  574. The invariant chain derived fragment CLIP is an efficient in vitro inhibitor of peptide binding to MHC class II molecules. Hitzel C, Koch N. Mol. Immunol. 33 25-31 (1996)
  575. Detergent-enhanced dissociation of endogenous peptides from PI-DRB1*0401. Buelow R, Kuo S, Paborsky L, Wilson KJ, Rothbard JB. Eur. J. Immunol. 24 2181-2185 (1994)
  576. Accuracy of a structural homology model for a class II histocompatibility protein, HLA-DR1: comparison to the crystal structure. Nauss JL, Reid RH, Sadegh-Nasseri S. J. Biomol. Struct. Dyn. 12 1213-1233 (1995)
  577. TepiTool: A Pipeline for Computational Prediction of T Cell Epitope Candidates. Paul S, Sidney J, Sette A, Peters B. Curr Protoc Immunol 114 18.19.1-18.19.24 (2016)
  578. Staying Alive: Measuring Intact Viable Microbes with Electrospray Ionization Mass Spectrometry. Forsberg E, Fang M, Siuzdak G. J. Am. Soc. Mass Spectrom. 28 14-20 (2017)
  579. Peptide motif analysis predicts alphaviruses as triggers for rheumatoid arthritis. Hogeboom C. Mol. Immunol. 68 465-475 (2015)
  580. Characterization and expression of MHC class II alpha and II beta genes in mangrove red snapper (Lutjanus argentimaculatus). Wang T, Tan S, Cai Z. Mol. Immunol. 68 373-381 (2015)
  581. Association of HLA-DRB1 genetic variants with the persistence of atopic dermatitis. Margolis DJ, Mitra N, Kim B, Gupta J, Hoffstad OJ, Papadopoulos M, Wubbenhorst B, Nathanson KL, Duke JL, Monos DS, Kamoun M. Hum. Immunol. 76 571-577 (2015)
  582. Nonsynonymous substitution rate heterogeneity in the peptide-binding region among different HLA-DRB1 lineages in humans. Yasukochi Y, Satta Y. G3 (Bethesda) 4 1217-1226 (2014)
  583. Characterization of class I- and class II-like major histocompatibility complex loci in pedigrees of North Atlantic right whales. Gillett RM, Murray BW, White BN. J. Hered. 105 188-202 (2014)
  584. Quantitative prediction of peptide binding to HLA-DP1 protein. Ivanov S, Dimitrov I, Doytchinova I. IEEE/ACM Trans Comput Biol Bioinform 10 811-815 (2013)
  585. Lack of HLA predominance and HLA shared epitopes in biliary Atresia. Mack CL, Anderson KM, Aubrey MT, Rosenthal P, Sokol RJ, Freed BM. Springerplus 2 42 (2013)
  586. Amino acid signatures in the Ovar-DRB1 peptide-binding pockets are associated with Ovine Pulmonary Adenocarcinoma susceptibility/resistance. Larruskain A, Minguijón E, Garcia-Etxebarria K, Arostegui I, Moreno B, Juste RA, Jugo BM. Biochem. Biophys. Res. Commun. 428 463-468 (2012)
  587. MHC class II DR allelic diversity in bighorn sheep. Subramaniam R, White SN, Herrmann-Hoesing LM, Srikumaran S. Gene 506 217-222 (2012)
  588. Identification of a novel HLA-DQB1 allele, DQB1*0326, in a College of American Pathologists 2009 survey specimen. Chen MJ, Chu CC, Shyr MH, Lin CL, Lin PY, Yang KL. Int. J. Immunogenet. 37 455-457 (2010)
  589. HLA genetics and disease with particular reference to Type 1 diabetes and HIV infection in Asian Indians. Mehra N, Kaur G. Expert Rev Clin Immunol 2 901-913 (2006)
  590. Soluble HLA-DQ2 expressed in S2 cells copurifies with a high affinity insect cell derived protein. Jüse U, Fleckenstein B, Bergseng E, Sollid LM. Immunogenetics 61 81-89 (2009)
  591. The replacement mutation in HLA-DRB1*1211 affects a likely keystone position. Horn PA, DeLuca DS, Jindra P, Blasczyk R. Hum. Immunol. 66 1254-1257 (2005)
  592. Major histocompatibility complex class I-restricted presentation of protein antigens without prior intracellular processing. Diegel ML, Chen F, Laus R, Graddis TJ, Vidovic D. Scand. J. Immunol. 58 1-8 (2003)
  593. Identification of three new DRB1 alleles, DRB1*0107, *0425 and *13012 and confirmation of DRB4*01033. Voorter CE, Hepkema BG, Lems SP, van den Berg-Loonen EM. Tissue Antigens 61 398-402 (2003)
  594. Oxazole- and imidazole-based Ser-Leu dipeptide mimetics in potent inhibitors of antigen presentation by MHC class II DR molecules. Sarabu R, Bolin DR, Campbell R, Cooper JR, Cox D, Gaizband D, Makofske R, Nagy Z, Olson GL. Drug Des Discov 18 3-7 (2002)
  595. Analysis of two acidic P6 pocket residues in the pH dependency of peptide binding by I-E(k). Dao CT, Weber DA, Jensen PE. Mol. Immunol. 38 1139-1149 (2002)
  596. Influence of histidine beta81 of HLA-DR101 on peptide binding and presentation to T-cell receptor. Figueredo Dos Santos C, Tilkin-Mariame AF, De Préval C, Lakhdar-Ghazal F. Hum. Immunol. 63 459-466 (2002)
  597. Identification of the novel allele HLA-DRB1*1137 which probably originated from DRB1*11011: implications for mismatch with its ancestor allele at bone marrow transplantation. Elsner HA, Kotsch K, Blasczyk R. Tissue Antigens 58 47-49 (2001)
  598. Prevention of experimental autoimmune encephalomyelitis by encephalitogenic epitope sequence simplified derivatives. Marino M, Ippolito A, Ruvo M, Scarallo A, Volpe S, Fassina G. Mol. Immunol. 37 951-960 (2000)
  599. Forthcoming topics Schutt CE, Lindberg U. Anat. Rec. 261 216 (2000)
  600. Selective peptidomimetic blockers of autoantigen presentation: a novel therapeutic approach to autoimmune disease. Lehmann PV. Trends Pharmacol. Sci. 21 79-80 (2000)
  601. Tetrapeptide derived inhibitors of complexation of a class II MHC: the peptide backbone is not inviolate. Jones AB, Acton JJ, Rivetna MN, Cummings RT, Cubbon RM, Nichols EA, Schwartz CD, Wicker LS, Hermes JD. Bioorg. Med. Chem. Lett. 9 2109-2114 (1999)
  602. The role of beta-pleated sheet DRB1 differences in acute rejection after cadaveric renal transplant. Adorno D, Canossi A, Piazza A, Poggi E, Papola F, Di Rocco M, Liberatore G, Del Beato T, Ozzella G, Anaclerio M, Casciani CU. Transplant. Proc. 31 730-733 (1999)
  603. A mutational analysis of the Abetaz/Aalphad major histocompatibility complex class II molecule that restricts autoreactive T cells in (NZBxNZW)F1 mice. The critical influence of alanine at position 69 in the Aalphad chain. Sai T, Mine M, Fukuoka M, Koarada S, Kimoto M. Immunology 96 325-332 (1999)
  604. Research Support, Non-U.S. Gov't Effect of chain length on the conformation and T cell recognition of synthetic hemagglutinin fragments. Tóth GK, Holly S, Majer Z, Hollósi M, Rajnavölgyi E, Laczkó I. Spectrochim Acta A Mol Biomol Spectrosc 56A 215-223 (2000)
  605. Peripheral blood cell bulk cultures are not suitable for the analysis of the genetic control of T-cell cytokine function. Zipp F, Windemuth C, Dichgans J, Wienker T, Martin R, Müller C. Immunol. Lett. 78 21-27 (2001)
  606. No specific reactivity to E. coli glutamic acid decarboxylase from sera of newly-diagnosed insulin dependent diabetic patients. Konidaris C, Mitlianga PG, Papadopoulos GK. Int J Immunopathol Pharmacol 16 129-138 (2003)
  607. Identification of a new HLA-DRB1 allele, HLA-DRB1*0436. Chu CC, Lee HL, Lin M. Tissue Antigens 63 279-281 (2004)
  608. Identification of an I-Ed-restricted T-cell epitope of Escherichia coli outer membrane protein F. Williams KM, Bigley EC. Infect. Immun. 72 3907-3913 (2004)
  609. Inhibitory effects on HLA-DR1-specific T-cell activation by influenza virus haemagglutinin-derived peptides. Li X, Li R, Li Z. Tissue Antigens 67 45-52 (2006)
  610. Conformation study of HA(306-318) antigenic peptide of the haemagglutinin influenza virus protein. Bertrand A, Brito RM, Alix AJ, Lancelin JM, Carvalho RA, Geraldes CF, Lakhdar-Ghazal F. Spectrochim Acta A Mol Biomol Spectrosc 65 711-718 (2006)
  611. Langmuir and Langmuir-Blodgett films of proline-rich N-terminal domain peptide of gamma-zein. Lakshmanan M, Dhathathreyan A. Colloids Surf B Biointerfaces 55 185-191 (2007)
  612. [Two faces of an illness: rheumatoid arthritis followed by ankylosing spondylitis]. Varga E, Petró A, Jáger R, Varga L. Orv Hetil 150 2000-2003 (2009)
  613. The HLA genes and their diverse polymorphism. Mehra NK. Indian J Clin Biochem 15 65-77 (2000)
  614. Molecular and cellular analyses of HLA class II-associated susceptibility to autoimmune diseases in the Japanese population. Nishimura Y, Ito H, Fujii S, Tabata H, Tokano Y, Chen YZ, Matsuda I, Mitsuya H, Kira J, Hashimoto H, Senju S, Matsushita S. Mod Rheumatol 11 103-112 (2001)
  615. Specificity, degeneracy, and molecular mimicry in antigen recognition by HLA-Class II restricted T cell receptors: implications for clinical medicine. Uemura Y, Senju S, Fujii S, Iwai LK, Maenaka K, Tabata H, Kanai T, Chen YZ, Nishimura Y. Mod Rheumatol 13 205-214 (2003)
  616. Quantifying Significance of MHC II Residues. Fan Y, Lu R, Wang L, Andreatta M, Li SC. IEEE/ACM Trans Comput Biol Bioinform 11 17-25 (2014)
  617. Enhanced Detection of Antigen-Specific CD4+ T Cells Using Altered Peptide Flanking Residue Peptide-MHC Class II Multimers. Holland CJ, Dolton G, Scurr M, Ladell K, Schauenburg AJ, Miners K, Madura F, Sewell AK, Price DA, Cole DK, Godkin AJ. J. Immunol. 195 5827-5836 (2015)
  618. A Simple Proteomics-Based Approach to Identification of Immunodominant Antigens from a Complex Pathogen: Application to the CD4 T Cell Response against Human Herpesvirus 6B. Becerra-Artiles A, Dominguez-Amorocho O, Stern LJ, Calvo-Calle JM. PLoS ONE 10 e0142871 (2015)
  619. Identification of amino acids in antigen-binding site of class II HLA proteins independently associated with hepatitis B vaccine response. Sakai A, Noguchi E, Fukushima T, Tagawa M, Iwabuchi A, Kita M, Kakisaka K, Miyasaka A, Takikawa Y, Sumazaki R. Vaccine 35 703-710 (2017)
  620. HLA-DQ β1 alleles associated with Epstein-Barr virus (EBV) infectivity and EBV gp42 binding to cells. Li Q, Bu W, Gabriel E, Aguilar F, Hoshino Y, Miyadera H, Hess C, Hornung RL, Roy A, Cohen JI. JCI Insight 2 e85687 (2017)
  621. Matrine regulates Th1/Th2 cytokine responses in rheumatoid arthritis by attenuating the NF-κB signaling. Niu Y, Dong Q, Li R. Cell Biol. Int. 41 611-621 (2017)
  622. BOLA-DRB3 gene polymorphisms influence bovine leukaemia virus infection levels in Holstein and Holstein × Jersey crossbreed dairy cattle. Carignano HA, Beribe MJ, Caffaro ME, Amadio A, Nani JP, Gutierrez G, Alvarez I, Trono K, Miretti MM, Poli MA. Anim. Genet. 48 420-430 (2017)
  623. Efficient estimation of binding free energies between peptides and an MHC class II molecule using coarse-grained molecular dynamics simulations with a weighted histogram analysis method. Huang M, Huang W, Wen F, Larson RG. J Comput Chem 38 2007-2019 (2017)
  624. Low genetic variation in the MHC class II DRB gene and MHC-linked microsatellites in endangered island populations of the leopard cat (Prionailurus bengalensis) in Japan. Saka T, Nishita Y, Masuda R. Immunogenetics (2017)
  625. Shared peptide binding of HLA Class I and II alleles associate with cutaneous nevirapine hypersensitivity and identify novel risk alleles. Pavlos R, McKinnon EJ, Ostrov DA, Peters B, Buus S, Koelle D, Chopra A, Schutte R, Rive C, Redwood A, Restrepo S, Bracey A, Kaever T, Myers P, Speers E, Malaker SA, Shabanowitz J, Jing Y, Gaudieri S, Hunt DF, Carrington M, Haas DW, Mallal S, Phillips EJ. Sci Rep 7 8653 (2017)
  626. An alternative view of T-cell receptor-MHC interaction: T-cell receptor binds transversally to the alpha-helices of the MHC molecule. Tang XX, Ikegaki N, Danska JS, Heber-Katz E. Mol. Immunol. 32 661-668 (1995)
  627. Clonal analysis of CD4 mediated accessory function on the effector activity of human CD4+ T cell subsets. Lamb JR, Faith A, Higgins JA, Verhoef A, Schneider P, Yssel H, O'Hehir RE. Clin. Exp. Allergy 25 839-847 (1995)
  628. DRB1*1316: evolutionary and functional implications of a novel polymorphism at codon 86. Dinauer DM, Glumm R, Baxter-Lowe LA. Hum. Immunol. 45 37-41 (1996)
  629. Application of murine T-T hybridoma cells to in vitro potency assay of human synthetic peptide vaccines. Yu SC, Nag B. Vaccine 14 1313-1321 (1996)
  630. Two new DR2 alleles: DRB1*1607 identified in an Ashkenazi Jewish family and DRB1*15022 found in a single Caucasian donor. Israel S, Smith AG, Miller K, Marashi A, Hansen JA, Brautbar C. Tissue Antigens 49 173-175 (1997)
  631. Three cases of familial ulcerative colitis--in a mother and two of her sons. Kamata A, Chiba M, Ishii N, Kudo T, Horie Y, Iizuka M, Masamune O. J. Gastroenterol. 32 401-404 (1997)
  632. Binding of single substituted promiscuous and designer peptides to purified DRB1*0101. Macklin KD, Conti-Fine BM. Biochem. Biophys. Res. Commun. 242 322-326 (1998)
  633. Peptide dependence of major histocompatibility complex class II specific alloreactive responses. Vidović D, Toral JI, Bolin DR, Ito K, Nagy ZA. Scand. J. Immunol. 47 191-194 (1998)
  634. Conserved T-cell receptor class II major histocompatibility complex contact detected in a T-lymphocyte population. Feng M, Chou D, Liaw Y, Lai M. Immunology 95 185-192 (1998)

Related citations provided by authors (1)

  1. Three-Dimensional Structure of the Human Class II Histocompatibility Antigen Hla-Dr1. Brown JH, Jardetzky TS, Gorga JC, Stern LJ, Urban RG, Strominger JL, Wiley DC Nature 364 33- (1993)